<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">Dgkq4Cys8b9wk57W76SZp9t</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2025000900309</article-id>
      <article-id pub-id-type="other">00309</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20250094</article-id>
      <article-id pub-id-type="other">abc.20250094</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo Original</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Resili&#234;ncia Cardiopulmonar em Indiv&#237;duos Altamente Ativos: An&#225;lise de Testes de Esfor&#231;o Cardiopulmonar Pr&#233; e P&#243;s-Covid-19</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Braga</surname>
            <given-names>Fabr&#237;cio</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <role>Obten&#231;&#227;o de dados</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Espinosa</surname>
            <given-names>Gabriel</given-names>
          </name>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Monteiro</surname>
            <given-names>Amanda</given-names>
          </name>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3688-2108</contrib-id>
          <name>
            <surname>Milani</surname>
            <given-names>Mauricio</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paiva</surname>
            <given-names>Juliana</given-names>
          </name>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Milani</surname>
            <given-names>Juliana Goulart Prata Oliveira</given-names>
          </name>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-6327-1428</contrib-id>
          <name>
            <surname>Franzoni</surname>
            <given-names>Leandro</given-names>
          </name>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stein</surname>
            <given-names>Ricardo</given-names>
          </name>
          <role>Obten&#231;&#227;o de financiamento</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-6323-7003</contrib-id>
          <name>
            <surname>Cipriano</surname>
            <given-names>Gerson</given-names>
            <suffix>Jr.</suffix>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gurgel</surname>
            <given-names>Jonas L&#237;rio</given-names>
          </name>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-2501-302X</contrib-id>
          <name>
            <surname>Mourilhe-Rocha</surname>
            <given-names>Ricardo</given-names>
          </name>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff10">
            <sup>10</sup>
          </xref>
        </contrib>
        <aff id="aff1">
          <label>1</label>
          <institution content-type="orgname">Laborat&#243;rio de Performance Humana</institution>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Laborat&#243;rio de Performance Humana, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff2">
          <label>2</label>
          <institution content-type="orgname">Universidade do Estado do Rio de Janeiro</institution>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff3">
          <label>3</label>
          <institution content-type="orgname">Universidade de Bras&#237;lia (UnB)</institution>
          <institution content-type="orgdiv1">Programa de P&#243;s-Gradua&#231;&#227;o em Ci&#234;ncias</institution>
          <institution content-type="orgdiv2">Tecnologias da Sa&#250;de</institution>
          <addr-line>
            <named-content content-type="city">Bras&#237;lia</named-content>
            <named-content content-type="state">DF</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Programa de P&#243;s-Gradua&#231;&#227;o em Ci&#234;ncias e Tecnologias da Sa&#250;de, Universidade de Bras&#237;lia (UnB), Bras&#237;lia, DF &#8211; Brasil</institution>
        </aff>
        <aff id="aff4">
          <label>4</label>
          <institution content-type="orgname">Hasselt University</institution>
          <institution content-type="orgdiv1">REVAL/BIOMED</institution>
          <addr-line>
            <named-content content-type="city">Hasselt</named-content>
          </addr-line>
          <country country="BE">B&#233;lgica</country>
          <institution content-type="original">Hasselt University, REVAL/BIOMED, Hasselt &#8211; B&#233;lgica</institution>
        </aff>
        <aff id="aff5">
          <label>5</label>
          <institution content-type="orgname">Heart Centre Hasselt, Jessa Hospital</institution>
          <addr-line>
            <named-content content-type="city">Hasselt</named-content>
          </addr-line>
          <country country="BE">B&#233;lgica</country>
          <institution content-type="original">Heart Centre Hasselt, Jessa Hospital, Hasselt &#8211; B&#233;lgica</institution>
        </aff>
        <aff id="aff6">
          <label>6</label>
          <institution content-type="orgname">Universidade Federal do Rio de Janeiro</institution>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff7">
          <label>7</label>
          <institution content-type="orgname">Universidade de Bras&#237;lia</institution>
          <addr-line>
            <named-content content-type="city">Bras&#237;lia</named-content>
            <named-content content-type="state">DF</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade de Bras&#237;lia, Bras&#237;lia, DF &#8211; Brasil</institution>
        </aff>
        <aff id="aff8">
          <label>8</label>
          <institution content-type="orgname">Universidade Federal do Rio Grande do Sul</institution>
          <addr-line>
            <named-content content-type="city">Porto Alegre</named-content>
            <named-content content-type="state">RS</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal do Rio Grande do Sul, Porto Alegre, RS &#8211; Brasil</institution>
        </aff>
        <aff id="aff9">
          <label>9</label>
          <institution content-type="orgname">Universidade Federal Fluminense</institution>
          <addr-line>
            <named-content content-type="city">Niter&#243;i</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal Fluminense, Niter&#243;i, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff10">
          <label>10</label>
          <institution content-type="orgname">Complexo Hospitalar Am&#233;ricas- Vit&#243;ria e Samaritano Barra</institution>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Complexo Hospitalar Am&#233;ricas- Vit&#243;ria e Samaritano Barra, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><label>Correspond&#234;ncia:</label><bold>Leandro Franzoni</bold> &#8226; Universidade Federal do Rio Grande do Sul (UFRGS) &#8211; Rua Itabora&#237;, 683. CEP <postal-code>90040-060</postal-code>, Porto Alegre, RS &#8211; Brasil E-mail: <email>franzoni.esef@gmail.com</email> </corresp>
        <fn fn-type="conflict">
          <label>Potencial conflito de interesse</label>
          <p>N&#227;o h&#225; conflito com o presente artigo.</p>
        </fn>
        <fn fn-type="edited-by">
          <label>Editor respons&#225;vel pela revis&#227;o:</label>
          <p>Gl&#225;ucia Maria Moraes de Oliveira</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>14</day>
        <month>11</month>
        <year>2025</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2025</year>
      </pub-date>
      <volume>122</volume>
      <issue>9</issue>
      <elocation-id>e20250094</elocation-id>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>06</month>
          <year>2025</year>
        </date>
        <date date-type="rev-recd">
          <day>06</day>
          <month>05</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>06</month>
          <year>2025</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#169; 2025 SciELO</copyright-statement>
        <copyright-year>2025</copyright-year>
        <copyright-holder>SciELO</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Resumo</title>
        <sec>
          <title>Fundamento:</title>
          <p>A pandemia de covid-19 afetou milh&#245;es de pessoas em todo o mundo, com impactos persistentes que se estendem al&#233;m da fase aguda. Um desses efeitos &#233; a condi&#231;&#227;o conhecida como p&#243;s-covid (ou covid longa), caracterizada por sintomas como fadiga e intoler&#226;ncia ao exerc&#237;cio com dura&#231;&#227;o superior a 60 dias. Embora o exerc&#237;cio f&#237;sico regular esteja associado &#224; redu&#231;&#227;o do risco de desfechos graves, relatos de queda no desempenho atl&#233;tico ap&#243;s a infec&#231;&#227;o &#8212; mesmo entre indiv&#237;duos altamente ativos (IAAs) &#8212; t&#234;m gerado preocupa&#231;&#245;es quanto aos efeitos de longo prazo sobre a sa&#250;de f&#237;sica. O teste de esfor&#231;o cardiopulmonar (TECP) &#233; uma ferramenta valiosa para avaliar a intoler&#226;ncia ao exerc&#237;cio e investigar as consequ&#234;ncias metab&#243;licas e ventilat&#243;rias da covid-19.</p>
        </sec>
        <sec>
          <title>Objetivo:</title>
          <p>Avaliar o impacto da covid-19 na fun&#231;&#227;o cardiopulmonar de IAAs por meio da an&#225;lise das respostas metab&#243;licas e ventilat&#243;rias obtidas em TECP realizado antes e ap&#243;s a infec&#231;&#227;o.</p>
        </sec>
        <sec>
          <title>M&#233;todos:</title>
          <p>Foram analisados retrospectivamente dados de TECP de IAAs de ambos os sexos. Os desfechos prim&#225;rios inclu&#237;ram altera&#231;&#245;es no consumo m&#225;ximo de oxig&#234;nio (<inline-formula id="in1"><mml:math display="inline" id="inm1"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico) e na efici&#234;ncia ventilat&#243;ria (rela&#231;&#227;o <inline-formula id="in2"><mml:math display="inline" id="inm2"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in3"><mml:math display="inline" id="inm3"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>). O n&#237;vel de signific&#226;ncia estat&#237;stica foi estabelecido em 5% (p &lt; 0,05).</p>
        </sec>
        <sec>
          <title>Resultados:</title>
          <p>Foram inclu&#237;dos 43 IAAs (72,1% do sexo masculino; 44 &#177; 10 anos). O intervalo mediano entre os testes foi de 479 dias, sendo o segundo TECP realizado em m&#233;dia 44 &#177; 27 dias ap&#243;s a infec&#231;&#227;o por covid-19. Observou-se uma redu&#231;&#227;o m&#233;dia de 1,5 ml/kg/min no <inline-formula id="in4"><mml:math display="inline" id="inm4"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico (p = 0,017), correspondendo a uma diminui&#231;&#227;o de 3,84% nos valores previstos de <inline-formula id="in5"><mml:math display="inline" id="inm5"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico (p = 0,045). A rela&#231;&#227;o <inline-formula id="in6"><mml:math display="inline" id="inm6"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in7"><mml:math display="inline" id="inm7"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> aumentou em m&#233;dia 1,2 (p = 0,017).</p>
        </sec>
        <sec>
          <title>Conclus&#227;o:</title>
          <p>Embora os IAAs n&#227;o sejam imunes aos efeitos da covid-19, seu elevado n&#237;vel basal de atividade f&#237;sica parece conferir uma consider&#225;vel resili&#234;ncia cardiopulmonar. As altera&#231;&#245;es observadas ap&#243;s a infec&#231;&#227;o foram m&#237;nimas, sugerindo que a manuten&#231;&#227;o da aptid&#227;o f&#237;sica pode oferecer benef&#237;cios protetores contra sequelas prolongadas da doen&#231;a.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave:</title>
        <kwd>Aptid&#227;o Cardiorrespirat&#243;ria</kwd>
        <kwd>Exerc&#237;cio F&#237;sico</kwd>
        <kwd>Teste de Esfor&#231;o</kwd>
        <kwd>Desempenho Atl&#233;tico</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico</funding-source>
          <award-id>444823/2023-9</award-id>
        </award-group>
        <funding-statement>O presente estudo foi financiado pela Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior - Brasil (CAPES) (ROR identifier: 00x0ma614) e Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico (CNPq) (n&#176;444823/2023-9).</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="2"/>
        <equation-count count="0"/>
        <ref-count count="29"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introdu&#231;&#227;o</title>
      <p>A pandemia de covid-19, iniciada em dezembro de 2019 em Wuhan, China, j&#225; afetou mais de 600 milh&#245;es de pessoas e resultou em mais de 6 milh&#245;es de mortes em todo o mundo ao longo de cinco ondas de infec&#231;&#227;o nos &#250;ltimos 3 anos.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Os sintomas da covid-19 s&#227;o conhecidos por persistirem al&#233;m da fase aguda, resultando em sequelas p&#243;s-agudas denominadas s&#237;ndrome p&#243;s-covid (ou covid longa), caracterizada por manifesta&#231;&#245;es cl&#237;nicas com dura&#231;&#227;o superior a 60 dias.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup> Embora os mecanismos subjacentes ainda n&#227;o estejam completamente elucidados, a fadiga e a intoler&#226;ncia ao exerc&#237;cio est&#227;o entre os sintomas mais frequentemente relatados.<sup><xref ref-type="bibr" rid="B4">4</xref></sup></p>
      <p>O teste de esfor&#231;o cardiopulmonar (TECP) &#233; considerado o padr&#227;o-ouro para avalia&#231;&#227;o da intoler&#226;ncia ao esfor&#231;o e &#233; recomendado na investiga&#231;&#227;o de indiv&#237;duos com covid longa.<sup><xref ref-type="bibr" rid="B5">5</xref>&#8211;<xref ref-type="bibr" rid="B7">7</xref></sup> Apesar dos efeitos protetores bem estabelecidos da pr&#225;tica regular de atividade f&#237;sica e da elevada aptid&#227;o cardiorrespirat&#243;ria (ACR) contra formas graves da doen&#231;a e suas sequelas, at&#233; mesmo atletas t&#234;m relatado redu&#231;&#227;o no desempenho f&#237;sico ap&#243;s infec&#231;&#227;o por covid-19.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Estudos baseados em TECP descreveram diversas altera&#231;&#245;es nessa popula&#231;&#227;o, incluindo redu&#231;&#227;o da ACR, in&#237;cio precoce do metabolismo anaer&#243;bio e padr&#245;es ventilat&#243;rios anormais. No entanto, poucos estudos compararam dados de TECP realizados antes e ap&#243;s a infec&#231;&#227;o em indiv&#237;duos fisicamente ativos.</p>
      <p>Dessa forma, o objetivo deste estudo foi comparar as respostas metab&#243;licas e ventilat&#243;rias obtidas por meio de TECP realizado antes e depois da infec&#231;&#227;o por covid-19 em indiv&#237;duos altamente ativos (IAAs).<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
      <fig id="f2">
        <graphic xlink:href="1678-4170-abc-122-09-e20250094-50094-gf01.tif"/></fig>
    </sec>
    <sec sec-type="methods">
      <title>M&#233;todos</title>
      <p>Este estudo transversal envolveu uma an&#225;lise <italic>ex post facto</italic> de dados de TECP coletados entre maio de 2020 e setembro de 2022 em dois centros de cardiologia do esporte. Foram considerados eleg&#237;veis os indiv&#237;duos que atendiam a todos os seguintes crit&#233;rios: (1) idade &#8805; 18 anos; (2) n&#237;vel 4 na Saltin-Grimby Physical Activity Level Scale (SGPALS), o que indica treinamento intenso e regular para esportes competitivos;<sup><xref ref-type="bibr" rid="B10">10</xref></sup> (3) TECP realizado como parte da avalia&#231;&#227;o p&#243;s-covid-19 antes da retomada de treinos competitivos com alto volume ou alta intensidade; e (4) disponibilidade de um TECP pr&#233;-covid-19 realizado no mesmo erg&#244;metro.</p>
      <p>O estudo foi aprovado pelos comit&#234;s de &#233;tica das duas institui&#231;&#245;es participantes (CAAE 33729120.5.0000.5253 e 35706720.4.0000.8093). Todos os procedimentos foram conduzidos de acordo com a Declara&#231;&#227;o de Helsinque da Associa&#231;&#227;o M&#233;dica Mundial, vers&#227;o de 2013.</p>
      <p>O TECP foi realizado em esteira ergom&#233;trica (Centurium 200) ou em cicloerg&#244;metro com freio eletromagn&#233;tico (Schoberer Rad Me&#223;technik [SRM], Alemanha), com an&#225;lise de gases respirat&#243;rios em tempo real (<italic>breath-by-breath</italic>) utilizando o sistema Metalyzer 3B (Cortex). Nos testes realizados em cicloerg&#244;metro, a geometria da bicicleta foi ajustada conforme as prefer&#234;ncias individuais, e os participantes foram orientados a utilizar vestu&#225;rio adequado para ciclismo. O protocolo teve in&#237;cio com 2 minutos de repouso, seguidos por 5 minutos de aquecimento em carga constante (100 W para homens e 50 W para mulheres). Em seguida, foi aplicado um protocolo em rampa, com incrementos de carga de 25 W/min para homens e 15 W/min para mulheres, at&#233; a exaust&#227;o volunt&#225;ria. Os participantes foram instru&#237;dos a manter uma cad&#234;ncia compat&#237;vel com seus treinos habituais, sendo o teste encerrado quando a cad&#234;ncia ca&#237;a abaixo de 70 rpm, mesmo com incentivo verbal. Nos testes realizados em esteira, utilizou-se um protocolo em rampa individualizado, com velocidade inicial entre 4 e 6 km/h, aumentada de forma linear conforme a idade e o n&#237;vel de desempenho atl&#233;tico autorreferido pelo participante. Para garantir sobrecarga progressiva ao longo do teste, foi inclu&#237;do um aumento de inclina&#231;&#227;o de 0,5% a cada 2 minutos. Todos os procedimentos seguiram as recomenda&#231;&#245;es nacionais de mitiga&#231;&#227;o da transmiss&#227;o viral.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
      <p>O protocolo e a metodologia para a an&#225;lise de gases ventilat&#243;rios, conforme previamente descrito,<sup><xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref></sup> inclu&#237;ram espirometria pr&#233;-exerc&#237;cio para avalia&#231;&#227;o da capacidade vital for&#231;ada (CVF) e do volume expirat&#243;rio for&#231;ado no primeiro segundo (VEF<sub>1</sub>). As vari&#225;veis analisadas no TECP inclu&#237;ram consumo de oxig&#234;nio (<inline-formula id="in8"><mml:math display="inline" id="inm8"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>), frequ&#234;ncia card&#237;aca (FC), frequ&#234;ncia respirat&#243;ria (FR), volume corrente (VC) e ventila&#231;&#227;o (<inline-formula id="in9"><mml:math display="inline" id="inm9"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E) nos primeiros (VT<sub>1</sub>) e segundos (VT<sub>2</sub>) limiares ventilat&#243;rios, bem como no pico do exerc&#237;cio. A efici&#234;ncia ventilat&#243;ria foi avaliada por meio do equivalente ventilat&#243;rio para o di&#243;xido de carbono (<inline-formula id="in10"><mml:math display="inline" id="inm10"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in11"><mml:math display="inline" id="inm11"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>) nos momentos de VT1, VT<sub>2</sub>, pico e tamb&#233;m pela inclina&#231;&#227;o da rela&#231;&#227;o <inline-formula id="in12"><mml:math display="inline" id="inm12"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in13"><mml:math display="inline" id="inm13"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>.</p>
      <p>Um m&#233;dico experiente determinou os limiares ventilat&#243;rios e os valores de pico. A inclina&#231;&#227;o <inline-formula id="in14"><mml:math display="inline" id="inm14"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in15"><mml:math display="inline" id="inm15"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> foi calculada at&#233; o VT<sub>2</sub>. Os valores de <inline-formula id="in16"><mml:math display="inline" id="inm16"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico e <inline-formula id="in17"><mml:math display="inline" id="inm17"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E foram definidos como a maior m&#233;dia m&#243;vel de 30 segundos registrada durante o &#250;ltimo minuto de esfor&#231;o. Os valores previstos de <inline-formula id="in18"><mml:math display="inline" id="inm18"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico foram baseados em padr&#245;es de refer&#234;ncia nacionais estabelecidos e utilizados para a classifica&#231;&#227;o da aptid&#227;o cardiorrespirat&#243;ria (ACR).<sup><xref ref-type="bibr" rid="B14">14</xref></sup></p>
      <p>A varia&#231;&#227;o percentual (&#916;%) no <inline-formula id="in19"><mml:math display="inline" id="inm19"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico e na rela&#231;&#227;o <inline-formula id="in20"><mml:math display="inline" id="inm20"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in21"><mml:math display="inline" id="inm21"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> foi calculada como a diferen&#231;a entre os valores p&#243;s-covid-19 e pr&#233;-covid-19, dividida pelo valor pr&#233;-COVID-19. Essas varia&#231;&#245;es foram comparadas com as diferen&#231;as cr&#237;ticas (<italic>critical differences</italic>, CD) propostas por Rose et al. (2018) &#8212; 13% para o <inline-formula id="in22"><mml:math display="inline" id="inm22"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico e 10% para a rela&#231;&#227;o <inline-formula id="in23"><mml:math display="inline" id="inm23"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in24"><mml:math display="inline" id="inm24"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>.<sup><xref ref-type="bibr" rid="B15">15</xref></sup> Esse limiar foi utilizado para determinar se as altera&#231;&#245;es observadas poderiam ter relev&#226;ncia cl&#237;nica e biol&#243;gica.</p>
      <sec>
        <title>An&#225;lise estat&#237;stica</title>
        <p>Dado o car&#225;ter explorat&#243;rio deste estudo, n&#227;o foi realizado c&#225;lculo de tamanho amostral a priori. Em vez disso, adotou-se um delineamento abrangente, incluindo todos os indiv&#237;duos que atendiam aos crit&#233;rios de elegibilidade. As vari&#225;veis cont&#237;nuas foram expressas como m&#233;dia &#177; desvio padr&#227;o (DP) para dados com distribui&#231;&#227;o normal, ou como mediana e intervalo interquart&#237;lico (25&#176; percentil; 75&#176; percentil) para dados com distribui&#231;&#227;o n&#227;o normal, conforme determinado pelo teste de Shapiro-Wilk. Para compara&#231;&#227;o de dados param&#233;tricos, utilizou-se o teste <italic>t</italic> pareado; para dados n&#227;o param&#233;tricos, foi aplicado o teste de postos sinalizados de Wilcoxon. As diferen&#231;as medianas para vari&#225;veis n&#227;o param&#233;tricas foram estimadas pelo m&#233;todo de Hodges-Lehmann.</p>
        <p>O n&#237;vel de signific&#226;ncia estat&#237;stica foi estabelecido em p &lt; 0,05 para todas as an&#225;lises. Todos os procedimentos estat&#237;sticos foram realizados utilizando o software IBM SPSS Statistics for Windows, vers&#227;o 29.0 (IBM Corp., Armonk, NY, EUA).</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Resultados</title>
      <p>A <xref ref-type="fig" rid="f1">Figura 1</xref> apresenta o fluxograma de inclus&#227;o dos participantes. Um total de 43 indiv&#237;duos altamente ativos (IAAs) atendeu aos crit&#233;rios de inclus&#227;o e foi inclu&#237;do na an&#225;lise (72,1% do sexo masculino; 42 &#177; 10 anos). O tempo m&#233;dio entre o diagn&#243;stico de covid-19 e a realiza&#231;&#227;o do TECP p&#243;s-infec&#231;&#227;o foi de 44 &#177; 27 dias. O intervalo mediano entre os TECPs pr&#233; e p&#243;s-infec&#231;&#227;o foi de 479 dias (IIQ: 546 dias). O TECP foi realizado em cicloerg&#244;metro em 55,8% dos casos. Quase todos os participantes apresentaram quadro agudo leve, e nenhum necessitou de hospitaliza&#231;&#227;o.</p>
      <fig id="f1">
        <label>Figura 1</label>
        <caption>
          <title>Fluxograma de inclus&#227;o dos participantes com base nos crit&#233;rios de elegibilidade. IAA: indiv&#237;duo altamente ativo; TECP: teste de esfor&#231;o cardiopulmonar.</title>
        </caption>
        <graphic xlink:href="1678-4170-abc-122-09-e20250094-50094-gf02.tif"/></fig>
      <p>A <xref ref-type="table" rid="t1">Tabela 1</xref> resume as vari&#225;veis do TECP antes e ap&#243;s a infec&#231;&#227;o por covid-19. N&#227;o foram observadas altera&#231;&#245;es significativas nos par&#226;metros espirom&#233;tricos (CVF e VEF<sub>1</sub>). No entanto, foram identificadas altera&#231;&#245;es discretas, por&#233;m estatisticamente significativas, em algumas vari&#225;veis do TECP. Tanto o <inline-formula id="in25"><mml:math display="inline" id="inm25"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> no VT<sub>2</sub> quanto o <inline-formula id="in26"><mml:math display="inline" id="inm26"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico apresentaram leves redu&#231;&#245;es. A varia&#231;&#227;o percentual mediana no <inline-formula id="in27"><mml:math display="inline" id="inm27"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico foi inferior ao limite de &#8722;13% considerado clinicamente significativo (p &#8804; 0,001). Apenas seis participantes (14%) apresentaram redu&#231;&#227;o no <inline-formula id="in28"><mml:math display="inline" id="inm28"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico superior a esse limiar ap&#243;s a covid-19.</p>
      <table-wrap id="t1">
        <label>Tabela 1</label>
        <caption>
          <title>Vari&#225;veis do teste de exerc&#237;cio cardiopulmonar antes e ap&#243;s a infec&#231;&#227;o por covid-19 em indiv&#237;duos altamente ativos</title>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup width="20%">
            <col/>
            <col/>
            <col/>
            <col/>
            <col/>
          </colgroup>
          <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
            <tr style="background-color:#76B4CF;">
              <th align="left" valign="middle">Vari&#225;vel</th>
              <th align="center" valign="middle">Antes da covid-19</th>
              <th align="center" valign="middle">Ap&#243;s a covid-19</th>
              <th align="center" valign="middle">Diferen&#231;a pareada (IC 95%)</th>
              <th align="center" valign="middle">Valor p</th>
            </tr>
          </thead>
          <tbody style="border-bottom: thin solid; border-color: #000000">
            <tr style="background-color:#76B4CF;">
              <td align="left" colspan="5" valign="middle">
                <bold>Espirometria</bold>
                <xref ref-type="table-fn" rid="TFN3">b</xref>
              </td>
            </tr>
            <tr>
              <td align="left" valign="middle">CVF, L<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">4,75 &#177; 1,00</td>
              <td align="center" valign="middle">4,78 &#177; 1,03</td>
              <td align="center" valign="middle">&#8722;0,07 (&#8722;0,26 a &#8722;0,12)</td>
              <td align="center" valign="middle">0,455</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">VEF<sub>1</sub>, L<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">3,79 &#177; 0,74</td>
              <td align="center" valign="middle">3,86 &#177; 0,84</td>
              <td align="center" valign="middle">0,003 (&#8722;0,10 a 0,10)</td>
              <td align="center" valign="middle">0,956</td>
            </tr>
            <tr style="background-color:#76B4CF;">
              <td align="left" colspan="5" style="border-top: thin solid; border-color: #000000" valign="middle">
                <bold>TECP</bold>
              </td>
            </tr>
            <tr>
              <td align="left" valign="middle">VO<sub>2</sub>pico, l/min<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">3,52 &#177; 0,74</td>
              <td align="center" valign="middle">3,42 &#177; 0,71</td>
              <td align="center" valign="middle">&#8722;0,10 (&#8722;0,20 a 0,002)</td>
              <td align="center" valign="middle">0,055</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">VO<sub>2</sub>pico, ml/kg/min<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">47,3 &#177; 7,1</td>
              <td align="center" valign="middle">45,8 &#177; 7,3</td>
              <td align="center" valign="middle">&#8722;1,5 (&#8722;2,79 a &#8722;0,29)</td>
              <td align="center" valign="middle">0,017</td>
            </tr>
            <tr>
              <td align="left" valign="middle">VO<sub>2</sub>pico, % do previsto<xref ref-type="table-fn" rid="TFN5">d</xref> </td>
              <td align="center" valign="middle">123,0 (111,3&#8211;141,2)</td>
              <td align="center" valign="middle">118,4 (109,6&#8211;137,0)</td>
              <td align="center" valign="middle">&#8722;3,84 (&#8722;7,9 a &#8722;0,08)</td>
              <td align="center" valign="middle">0,045</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">FC pico, bpm<xref ref-type="table-fn" rid="TFN5">d</xref> </td>
              <td align="center" valign="middle">174 (165&#8211;181)</td>
              <td align="center" valign="middle">173 (163&#8211;182)</td>
              <td align="center" valign="middle">&#8722;0,5 (&#8722;2,5 a 1,5)</td>
              <td align="center" valign="middle">0,647</td>
            </tr>
            <tr>
              <td align="left" valign="middle"><inline-formula id="in29"><mml:math display="inline" id="inm29"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E pico, l/min<xref ref-type="table-fn" rid="TFN4">c</xref></td>
              <td align="center" valign="middle">138,4 &#177; 32,6</td>
              <td align="center" valign="middle">134,4 &#177; 29,8</td>
              <td align="center" valign="middle">&#8722;4,0 (&#8722;9,5 a 1,6)</td>
              <td align="center" valign="middle">0,159</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">VC pico, l<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">2,66 &#177; 0,59</td>
              <td align="center" valign="middle">2,67 &#177; 0,62</td>
              <td align="center" valign="middle">0,01 (&#8722;0,07 a 0,08)</td>
              <td align="center" valign="middle">0,792</td>
            </tr>
            <tr>
              <td align="left" valign="middle">FR pico, respira&#231;&#245;es/min<xref ref-type="table-fn" rid="TFN5">d</xref> </td>
              <td align="center" valign="middle">54,0 (46,5&#8211;58,0)</td>
              <td align="center" valign="middle">49,7 (45,0&#8211;57,0)</td>
              <td align="center" valign="middle">&#8722;1,5 (&#8722;3,5 a 0,35)</td>
              <td align="center" valign="middle">0,079</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle"><inline-formula id="in30"><mml:math display="inline" id="inm30"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in31"><mml:math display="inline" id="inm31"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> pico<xref ref-type="table-fn" rid="TFN5">d</xref> </td>
              <td align="center" valign="middle">32,6 (31,3&#8211;34,7)</td>
              <td align="center" valign="middle">34,2 (32,0&#8211;36,6)</td>
              <td align="center" valign="middle">1,2 (0,25 a 2,20)</td>
              <td align="center" valign="middle">0,017</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Inclina&#231;&#227;o <inline-formula id="in32"><mml:math display="inline" id="inm32"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in33"><mml:math display="inline" id="inm33"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub><xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">30,7 &#177; 4,0</td>
              <td align="center" valign="middle">31,3 &#177; 4,0</td>
              <td align="center" valign="middle">0,63 (&#8722;0,30 a 1,56)</td>
              <td align="center" valign="middle">0,176</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">OUES<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">3727 &#177; 868</td>
              <td align="center" valign="middle">3474 &#177; 1025</td>
              <td align="center" valign="middle">&#8722;253 (&#8722;508 a 1)</td>
              <td align="center" valign="middle">0,051</td>
            </tr>
            <tr>
              <td align="left" valign="middle">RER pico<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">1,16 &#177; 0,07</td>
              <td align="center" valign="middle">1,15 &#177; 0,07</td>
              <td align="center" valign="middle">&#8722;0,01 (&#8722;0,03 a 0,01)</td>
              <td align="center" valign="middle">0,453</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">VO<sub>2</sub> no VT<sub>1</sub>, l/min<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">2,26 &#177; 0,54</td>
              <td align="center" valign="middle">2,21 &#177; 0,49</td>
              <td align="center" valign="middle">&#8722;0,06 (&#8722;0,19 a 0,07)</td>
              <td align="center" valign="middle">0,366</td>
            </tr>
            <tr>
              <td align="left" valign="middle">VO<sub>2</sub> no VT<sub>1</sub>, ml/kg/min<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">30,6 &#177; 6,2</td>
              <td align="center" valign="middle">29,3 &#177; 7,5</td>
              <td align="center" valign="middle">&#8722;1,34 (&#8722;3,54 a 0,86)</td>
              <td align="center" valign="middle">0,226</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">FC no VT<sub>1</sub>, bpm<xref ref-type="table-fn" rid="TFN5">d</xref> </td>
              <td align="center" valign="middle">133 (119&#8211;144)</td>
              <td align="center" valign="middle">133 (119&#8211;144)</td>
              <td align="center" valign="middle">0,00 (&#8722;4,0 a 4,5)</td>
              <td align="center" valign="middle">0,913</td>
            </tr>
            <tr>
              <td align="left" valign="middle"><inline-formula id="in34"><mml:math display="inline" id="inm34"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>C no VT<sub>1</sub>, l/min<xref ref-type="table-fn" rid="TFN5">d</xref></td>
              <td align="center" valign="middle">58,8 (46,3&#8211;71,1)</td>
              <td align="center" valign="middle">61,2 (49,5&#8211;69,3)</td>
              <td align="center" valign="middle">0,7 (&#8722;4,3 a 5,8)</td>
              <td align="center" valign="middle">0,213</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">FR no VT<sub>1</sub>, respira&#231;&#245;es/min<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">28,8 &#177; 6,9</td>
              <td align="center" valign="middle">28,1 &#177; 7,0</td>
              <td align="center" valign="middle">&#8722;0,7 (&#8722;2,0 a 0,7)</td>
              <td align="center" valign="middle">0,330</td>
            </tr>
            <tr>
              <td align="left" valign="middle">VC no VT<sub>1</sub>, l<xref ref-type="table-fn" rid="TFN5">d</xref> </td>
              <td align="center" valign="middle">1,96 (1,70&#8211;2,55)</td>
              <td align="center" valign="middle">2,20 (1,70&#8211;2,63)</td>
              <td align="center" valign="middle">0,07 (&#8722;0,06 a 0,21)</td>
              <td align="center" valign="middle">0,817</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle"><inline-formula id="in35"><mml:math display="inline" id="inm35"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in36"><mml:math display="inline" id="inm36"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> no VT1<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">29,3 &#177; 4,0</td>
              <td align="center" valign="middle">29,3 &#177; 3,4</td>
              <td align="center" valign="middle">0,01 (&#8722;0,94 a 0,96)</td>
              <td align="center" valign="middle">0,980</td>
            </tr>
            <tr>
              <td align="left" valign="middle">VO<sub>2</sub> no VT<sub>2</sub>, l/min<xref ref-type="table-fn" rid="TFN5">d</xref> </td>
              <td align="center" valign="middle">3,36 (2,76&#8211;3,59)</td>
              <td align="center" valign="middle">2,96 (2,67&#8211;3,50)</td>
              <td align="center" valign="middle">&#8722;0,11 (&#8722;0,25 a 0,02)</td>
              <td align="center" valign="middle">0,085</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">VO<sub>2</sub> no VT<sub>2</sub>, ml/kg/minc</td>
              <td align="center" valign="middle">42,4 &#177; 6,0</td>
              <td align="center" valign="middle">40,6 &#177; 6,5</td>
              <td align="center" valign="middle">&#8722;1,71 (&#8722;3,32 a &#8722;0,10)</td>
              <td align="center" valign="middle">0,038</td>
            </tr>
            <tr>
              <td align="left" valign="middle">FC no VT<sub>2</sub>, bpm<xref ref-type="table-fn" rid="TFN5">d</xref> </td>
              <td align="center" valign="middle">163 (155&#8211;173)</td>
              <td align="center" valign="middle">161 (150&#8211;169)</td>
              <td align="center" valign="middle">&#8722;0,5 (&#8722;3,5 a 2,5)</td>
              <td align="center" valign="middle">0,507</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle"><inline-formula id="in37"><mml:math display="inline" id="inm37"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E no VT<sub>2</sub>, l/min<xref ref-type="table-fn" rid="TFN5">d</xref></td>
              <td align="center" valign="middle">107,8 (82,8&#8211;119,4)</td>
              <td align="center" valign="middle">93,2 (83,8&#8211;113,3)</td>
              <td align="center" valign="middle">&#8722;3,7 (&#8722;8,5 a 1,43)</td>
              <td align="center" valign="middle">0,158</td>
            </tr>
            <tr>
              <td align="left" valign="middle">FR no VT<sub>2</sub>, respira&#231;&#245;es/min<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">39,4 &#177; 8,1</td>
              <td align="center" valign="middle">37,6 &#177; 8,0</td>
              <td align="center" valign="middle">&#8722;1,8 (&#8722;3,50 a &#8722;0,06)</td>
              <td align="center" valign="middle">0,043</td>
            </tr>
            <tr style="background-color:#C7DFEC;">
              <td align="left" valign="middle">VC no VT<sub>2</sub>, l<xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">2,61 &#177; 0,60</td>
              <td align="center" valign="middle">2,62 &#177; 0,59</td>
              <td align="center" valign="middle">0,01 (&#8722;0,08 a 0,10)</td>
              <td align="center" valign="middle">0,833</td>
            </tr>
            <tr>
              <td align="left" valign="middle"><inline-formula id="in38"><mml:math display="inline" id="inm38"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in39"><mml:math display="inline" id="inm39"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> no VT<sub>2</sub><xref ref-type="table-fn" rid="TFN4">c</xref> </td>
              <td align="center" valign="middle">30,3 &#177; 3,1</td>
              <td align="center" valign="middle">30,6 &#177; 3,2</td>
              <td align="center" valign="middle">0,31 (&#8722;0,42 a 1,04)</td>
              <td align="center" valign="middle">0,398</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN1">
            <p>Os dados s&#227;o apresentados como m&#233;dia &#177; DP ou mediana (IIQ), conforme apropriado.</p>
          </fn>
          <fn id="TFN2">
            <label>a</label>
            <p>Diferen&#231;a pareada = valor p&#243;s-covid-19 menos valor pr&#233;-covid-19; IC 95% fornecido.</p>
          </fn>
          <fn id="TFN3">
            <label>b</label>
            <p>Dados espirom&#233;tricos dispon&#237;veis para 30 indiv&#237;duos.</p>
          </fn>
          <fn id="TFN4">
            <label>c</label>
            <p>Teste t pareado.</p>
          </fn>
          <fn id="TFN5">
            <label>d</label>
            <p>Teste de postos sinalizados de Wilcoxon; m&#233;todo de Hodges-Lehmann aplicado para diferen&#231;as medianas. FR: frequ&#234;ncia respirat&#243;ria; TECP: teste de esfor&#231;o cardiopulmonar; VEF1: volume expirat&#243;rio for&#231;ado no primeiro segundo; CVF: capacidade vital for&#231;ada; FC: frequ&#234;ncia card&#237;aca; OUES: inclina&#231;&#227;o da efici&#234;ncia de capta&#231;&#227;o de oxig&#234;nio; RER: raz&#227;o de troca respirat&#243;ria; <inline-formula id="in40"><mml:math display="inline" id="inm40"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E: ventila&#231;&#227;o minuto; <inline-formula id="in41"><mml:math display="inline" id="inm41"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in42"><mml:math display="inline" id="inm42"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>: equivalente ventilat&#243;rio para di&#243;xido de carbono; <inline-formula id="in43"><mml:math display="inline" id="inm43"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>: consumo de oxig&#234;nio; VT: limiar ventilat&#243;rio; VC: volume corrente.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>A rela&#231;&#227;o <inline-formula id="in44"><mml:math display="inline" id="inm44"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in45"><mml:math display="inline" id="inm45"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> no pico aumentou significativamente ap&#243;s a infec&#231;&#227;o. No entanto, nenhum outro par&#226;metro de efici&#234;ncia ventilat&#243;ria apresentou altera&#231;&#227;o significativa. A varia&#231;&#227;o percentual mediana na rela&#231;&#227;o <inline-formula id="in46"><mml:math display="inline" id="inm46"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in47"><mml:math display="inline" id="inm47"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> no pico foi inferior ao limite de 10% estabelecido como CD (p &lt; 0,001). Apenas dois participantes (4,7%) apresentaram aumento acima desse limite.</p>
      <p>A FR no VT<sub>2</sub> apresentou leve redu&#231;&#227;o ap&#243;s a covid-19. Embora estatisticamente significativa, essa altera&#231;&#227;o n&#227;o foi considerada clinicamente ou biologicamente relevante e n&#227;o pode ser atribu&#237;da de forma definitiva aos efeitos p&#243;s-covid-19 ou &#224; redu&#231;&#227;o no volume de treinamento durante o per&#237;odo de recupera&#231;&#227;o.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discuss&#227;o</title>
      <p>Este estudo avaliou o impacto da infec&#231;&#227;o por covid-19 em IAAs e identificou redu&#231;&#245;es discretas no consumo de oxig&#234;nio tanto no pico do exerc&#237;cio quanto no VT<sub>2</sub>, al&#233;m de um leve aumento na raz&#227;o <inline-formula id="in48"><mml:math display="inline" id="inm48"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in49"><mml:math display="inline" id="inm49"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> no pico. Embora estatisticamente significativas, essas altera&#231;&#245;es n&#227;o indicaram comprometimento cardiopulmonar relevante. Ademais, todas as varia&#231;&#245;es observadas permaneceram abaixo dos limiares de CD previamente estabelecidos, o que sugere que &#233; improv&#225;vel que representem efeitos clinicamente significativos da covid-19 sobre a fun&#231;&#227;o cardiopulmonar. A Figura Central resume os principais achados do estudo.</p>
      <p>Poucos estudos avaliaram os resultados do TECP em IAAs antes e ap&#243;s a infec&#231;&#227;o por covid-19. &#346;li&#380; et al.<sup><xref ref-type="bibr" rid="B16">16</xref></sup> relataram uma redu&#231;&#227;o significativa no <inline-formula id="in50"><mml:math display="inline" id="inm50"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico, bem como no <inline-formula id="in51"><mml:math display="inline" id="inm51"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> nos limiares ventilat&#243;rios VT<sub>1</sub> e VT<sub>2</sub> entre atletas de endurance. De forma semelhante aos nossos achados, esse estudo documentou uma redu&#231;&#227;o de 5,9% no <inline-formula id="in52"><mml:math display="inline" id="inm52"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico &#8212; uma altera&#231;&#227;o que n&#227;o p&#244;de ser atribu&#237;da de forma conclusiva &#224; covid-19. Nosso estudo oferece contribui&#231;&#245;es adicionais, ao incluir uma maior propor&#231;&#227;o de participantes do sexo feminino (27,9% vs 12,2%) e um intervalo mais curto entre a infec&#231;&#227;o e a realiza&#231;&#227;o do TECP p&#243;s-covid-19 (44 vs 155 dias), ampliando, assim, a compreens&#227;o atual sobre o poss&#237;vel impacto da covid-19 na fun&#231;&#227;o cardiopulmonar de IAAs.</p>
      <p>Parpa e Michaelides<sup><xref ref-type="bibr" rid="B17">17</xref></sup> avaliaram a ACR em jogadores de futebol profissional antes e ap&#243;s a infec&#231;&#227;o por covid-19 e relataram redu&#231;&#245;es significativas nos valores de <inline-formula id="in53"><mml:math display="inline" id="inm53"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>m&#225;x e no tempo de corrida em esteira ap&#243;s a infec&#231;&#227;o, mesmo ap&#243;s 60 dias de recupera&#231;&#227;o, sugerindo um impacto duradouro sobre a ACR. Em conjunto, esses resultados ressaltam os poss&#237;veis efeitos de longo prazo da covid-19 sobre o desempenho aer&#243;bico em atletas. Vale destacar que nem o estudo de Parpa e Michaelides<sup><xref ref-type="bibr" rid="B17">17</xref></sup> nem o de &#346;li&#380; et al.<sup><xref ref-type="bibr" rid="B16">16</xref></sup> inclu&#237;ram avalia&#231;&#245;es da efici&#234;ncia ventilat&#243;ria.</p>
      <p>No estudo de D&#8217;Isabel et al.<sup><xref ref-type="bibr" rid="B18">18</xref></sup> realizado com bombeiros do Arizona, foram observadas redu&#231;&#245;es significativas no <inline-formula id="in54"><mml:math display="inline" id="inm54"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico e no <inline-formula id="in55"><mml:math display="inline" id="inm55"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> no VT1 ap&#243;s a infec&#231;&#227;o. A diminui&#231;&#227;o m&#233;dia no VO<sub>2</sub>pico foi de 2,55 ml/kg/min, correspondendo a uma redu&#231;&#227;o de 7,3% &#8212; a maior registrada at&#233; o momento. O <inline-formula id="in56"><mml:math display="inline" id="inm56"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> no VT<sub>1</sub> apresentou queda ainda mais acentuada, de 24,3%. Adicionalmente, observou-se piora na efici&#234;ncia ventilat&#243;ria, evidenciada pelo aumento da inclina&#231;&#227;o da rela&#231;&#227;o <inline-formula id="in57"><mml:math display="inline" id="inm57"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in58"><mml:math display="inline" id="inm58"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> de 24,7 no per&#237;odo pr&#233;-infec&#231;&#227;o para 26,0 no p&#243;s-infec&#231;&#227;o. Diferentemente dos atletas de competi&#231;&#227;o, os bombeiros do Arizona possuem rotinas de treinamento f&#237;sico e exig&#234;ncias ocupacionais distintas, o que pode ter influenciado suas trajet&#243;rias de recupera&#231;&#227;o. Fatores demogr&#225;ficos e caracter&#237;sticas regionais tamb&#233;m podem ter contribu&#237;do para os desfechos observados. A natureza fisicamente extenuante do trabalho, somada &#224; press&#227;o adicional de responder a chamadas de emerg&#234;ncia durante a pandemia, provavelmente gerou estresse elevado, o que pode ter prejudicado a recupera&#231;&#227;o cardiopulmonar e diferenciado essa experi&#234;ncia daquela vivida por popula&#231;&#245;es atl&#233;ticas.<sup><xref ref-type="bibr" rid="B19">19</xref></sup></p>
      <p>Por outro lado, Csulak et al.<sup><xref ref-type="bibr" rid="B20">20</xref></sup> conduziram um estudo com nadadores de elite, avaliando o desempenho cardiopulmonar antes e ap&#243;s a infec&#231;&#227;o por covid-19. Os resultados n&#227;o demonstraram altera&#231;&#245;es significativas nos principais par&#226;metros do TECP, incluindo <inline-formula id="in59"><mml:math display="inline" id="inm59"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>m&#225;x e <inline-formula id="in60"><mml:math display="inline" id="inm60"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in61"><mml:math display="inline" id="inm61"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>, o que sugere que infec&#231;&#245;es leves por covid-19 tiveram impacto m&#237;nimo na fun&#231;&#227;o cardiopulmonar de atletas de alto rendimento.</p>
      <p>As altera&#231;&#245;es observadas na capacidade aer&#243;bica ap&#243;s a covid-19 entre IAAs podem n&#227;o ser atribu&#237;das exclusivamente ao v&#237;rus. Um estudo com atletas de endurance indicou que apenas duas semanas de destreinamento podem reduzir significativamente a fun&#231;&#227;o cardiopulmonar e a aptid&#227;o muscular. Isso sugere que a redu&#231;&#227;o do treinamento durante o per&#237;odo de recupera&#231;&#227;o pode ter contribu&#237;do para o desempenho aer&#243;bico diminu&#237;do observado em nosso estudo.<sup><xref ref-type="bibr" rid="B21">21</xref></sup> Assim, &#233; fundamental considerar o impacto da diminui&#231;&#227;o da atividade f&#237;sica ao interpretar altera&#231;&#245;es na fun&#231;&#227;o cardiopulmonar p&#243;s- covid-19.</p>
      <p>As mudan&#231;as m&#237;nimas observadas na pot&#234;ncia aer&#243;bica m&#225;xima (<inline-formula id="in62"><mml:math display="inline" id="inm62"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico) e a preserva&#231;&#227;o da capacidade oxidativa subm&#225;xima (<inline-formula id="in63"><mml:math display="inline" id="inm63"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> no VT<sub>1</sub>) em nossa coorte podem ser atribu&#237;das a diversos fatores. Pesquisas anteriores demonstraram que a atividade f&#237;sica pode atuar como fator protetor contra quadros graves, inclusive na covid-19.<sup><xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref></sup> Redu&#231;&#245;es na ACR ap&#243;s a infec&#231;&#227;o t&#234;m sido associadas a formas graves da doen&#231;a, idade avan&#231;ada, sedentarismo e comorbidades.<sup><xref ref-type="bibr" rid="B24">24</xref></sup> Por outro lado, o estilo de vida atl&#233;tico, a aus&#234;ncia de comorbidades e a relativa juventude dos participantes de nosso estudo provavelmente contribu&#237;ram para a preserva&#231;&#227;o da ACR. Al&#233;m disso, a pandemia afetou o comportamento em rela&#231;&#227;o ao exerc&#237;cio f&#237;sico de maneiras diversas. Estima-se que o aumento da pr&#225;tica de atividade f&#237;sica durante esse per&#237;odo tenha variado de 9% a 33%.<sup><xref ref-type="bibr" rid="B25">25</xref></sup> Por exemplo, os treinos virtuais de ciclismo apresentaram crescimento expressivo, impulsionados pelas medidas de confinamento, avan&#231;os tecnol&#243;gicos e o apoio de grandes eventos como o Tour de France,<sup><xref ref-type="bibr" rid="B26">26</xref></sup> acompanhados por um aumento de 170% nas vendas de equipamentos para treino indoor.<sup><xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref></sup> Shaw et al.<sup><xref ref-type="bibr" rid="B29">29</xref></sup> tamb&#233;m relataram aus&#234;ncia de mudan&#231;a no volume de treinamento entre ciclistas m&#225;sters durante o confinamento. Esses achados sugerem que alguns indiv&#237;duos podem ter atingido um pico de condicionamento aer&#243;bico antes da infec&#231;&#227;o, e que os valores observados no p&#243;s-covid-19 em nosso estudo podem refletir um retorno ao n&#237;vel basal, em vez de um decl&#237;nio real na fun&#231;&#227;o cardiopulmonar.</p>
      <p>Este estudo apresenta diversas limita&#231;&#245;es relevantes. Primeiramente, a equival&#234;ncia entre os par&#226;metros fisiol&#243;gicos pr&#233;-covid-19 e os verdadeiros valores basais &#233; incerta. Em segundo lugar, os comportamentos de treinamento no per&#237;odo p&#243;s- covid-19 e a gravidade da doen&#231;a foram autorrelatados, o que introduz potencial vi&#233;s de mem&#243;ria. Em terceiro lugar, a inclus&#227;o exclusiva de casos leves de covid-19 limita a generaliza&#231;&#227;o dos achados para indiv&#237;duos que vivenciaram quadros moderados ou graves. Em quarto lugar, a aus&#234;ncia de um grupo controle com menor n&#237;vel de atividade f&#237;sica restringe a possibilidade de realizar infer&#234;ncias comparativas. Em quinto lugar, a coleta de dados ocorreu durante os est&#225;gios iniciais da pandemia, antes da disponibilidade de vacinas e do surgimento de variantes virais posteriores. Embora isso limite a aplicabilidade a outras fases da pandemia, tamb&#233;m oferece um panorama &#250;nico do impacto inicial da covid-19 em IAAs. Em sexto lugar, a popula&#231;&#227;o do estudo &#8212; caracterizada por idade m&#233;dia de 42 anos e <inline-formula id="in64"><mml:math display="inline" id="inm64"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>pico de 47 ml/kg/min &#8212; representa um grupo altamente ativo, mas que n&#227;o corresponde ao n&#237;vel de atletas de elite. Portanto, os achados podem n&#227;o ser generaliz&#225;veis nem para atletas de alto rendimento, nem para indiv&#237;duos menos ativos. Em s&#233;timo lugar, o uso de diferentes erg&#244;metros (cicloerg&#244;metro vs esteira) e a aus&#234;ncia de an&#225;lises estratificadas por sexo podem ter introduzido variabilidade adicional nas medidas fisiol&#243;gicas. Por fim, a aus&#234;ncia de um grupo controle verdadeiro limita a capacidade de distinguir altera&#231;&#245;es p&#243;s-covid-19 de flutua&#231;&#245;es fisiol&#243;gicas normais relacionadas a interrup&#231;&#245;es no treinamento ou a outros fatores n&#227;o relacionados. Estudos futuros que incorporem grupos controle e um espectro mais amplo de n&#237;veis de aptid&#227;o f&#237;sica ser&#227;o essenciais para fornecer evid&#234;ncias mais abrangentes e generaliz&#225;veis.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclus&#227;o</title>
      <p>Esta an&#225;lise abrangente de IAAs comparou os resultados do TECP antes e ap&#243;s o in&#237;cio da pandemia de covid-19. Os resultados demonstraram uma not&#225;vel resili&#234;ncia cardiopulmonar do organismo em indiv&#237;duos com elevado n&#237;vel de aptid&#227;o f&#237;sica. Embora tenham sido observadas altera&#231;&#245;es discretas na fun&#231;&#227;o cardiopulmonar, estas permaneceram abaixo dos limiares de CD, o que sugere uma capacidade preservada de resistir e se recuperar dos impactos fisiol&#243;gicos da covid-19. Esses achados refor&#231;am o potencial papel protetor de um estilo de vida ativo frente aos efeitos adversos de doen&#231;as infecciosas emergentes.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="financial-disclosure" id="fn5">
        <label>Fontes de financiamento</label>
        <p>O presente estudo foi financiado pela Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior - Brasil (CAPES) (ROR identifier: 00x0ma614) e Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico (CNPq) (n&#176;444823/2023-9).</p>
      </fn>
      <fn fn-type="other" id="fn6">
        <label>Vincula&#231;&#227;o acad&#234;mica</label>
        <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
      </fn>
      <fn fn-type="other" id="fn7">
        <label>Aprova&#231;&#195;o &#201;tica e Consentimento Informado</label>
        <p>Este estudo foi aprovado pelo Comit&#234; de &#201;tica do Laborat&#243;rio de Performance Humana e Universidade de Bras&#237;lia, respectivamente sob o n&#250;mero de protocolo 33729120.5.0000.5253 e 35706720.4.0000.8093. Todos os procedimentos envolvidos nesse estudo est&#227;o de acordo com a Declara&#231;&#227;o de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes inclu&#237;dos no estudo.</p>
      </fn>
      <fn fn-type="other" id="fn8">
        <label>Uso de Intelig&#234;ncia Artificial</label>
        <p>Os autores n&#227;o utilizaram ferramentas de intelig&#234;ncia artificial no desenvolvimento deste trabalho.</p>
      </fn>
    </fn-group>
    <sec sec-type="data-availability" specific-use="data-available">
      <label>Disponibilidade de Dados</label>
      <p>Os conte&#250;dos subjacentes ao texto da pesquisa est&#227;o contidos no manuscrito.</p>
    </sec>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Our World in Data</collab>
          </person-group>
          <source>COVID-19 Data Explorer [Internet]</source>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Our World in Data</publisher-name>
          <year>2025</year>
          <date-in-citation content-type="access-date">[cited 2025 Jul 21]</date-in-citation>
          <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://ourworldindata.org/explorers/coronavirus-data-explorer">https://ourworldindata.org/explorers/coronavirus-data-explorer</ext-link> </comment>
        </element-citation>
        <mixed-citation>1 Our World in Data. COVID-19 Data Explorer [Internet]. Oxford: Our World in Data; 2025 [cited 2025 Jul 21]. Available from: <ext-link ext-link-type="uri" xlink:href="https://ourworldindata.org/explorers/coronavirus-data-explorer">https://ourworldindata.org/explorers/coronavirus-data-explorer</ext-link>.</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carf&#236;</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bernabei</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Landi</surname>
              <given-names>F</given-names>
            </name>
            <collab>Gemelli Against COVID-19 Post-Acute Care Study Group</collab>
          </person-group>
          <article-title>Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients after Acute COVID-19</article-title>
          <source>JAMA</source>
          <year>2020</year>
          <volume>324</volume>
          <issue>6</issue>
          <fpage>603</fpage>
          <lpage>605</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2020.12603</pub-id>
        </element-citation>
        <mixed-citation>2 Carf&#236; A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients after Acute COVID-19. JAMA. 2020;324(6):603-5. doi: 10.1001/jama.2020.12603.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crook</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Raza</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nowell</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Edison</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Long Covid-Mechanisms, Risk Factors, and Management</article-title>
          <source>BMJ</source>
          <year>2021</year>
          <volume>374</volume>
          <fpage>n1648</fpage>
          <lpage>n1648</lpage>
          <pub-id pub-id-type="doi">10.1136/bmj.n1648</pub-id>
        </element-citation>
        <mixed-citation>3 Crook H, Raza S, Nowell J, Young M, Edison P. Long Covid-Mechanisms, Risk Factors, and Management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandler</surname>
              <given-names>CX</given-names>
            </name>
            <name>
              <surname>Wyller</surname>
              <given-names>VBB</given-names>
            </name>
            <name>
              <surname>Moss-Morris</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Buchwald</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Crawley</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hautvast</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long COVID and Post-Infective Fatigue Syndrome: A Review</article-title>
          <source>Open Forum Infect Dis</source>
          <year>2021</year>
          <volume>8</volume>
          <issue>10</issue>
          <fpage>ofab440</fpage>
          <lpage>ofab440</lpage>
          <pub-id pub-id-type="doi">10.1093/ofid/ofab440</pub-id>
        </element-citation>
        <mixed-citation>4 Sandler CX, Wyller VBB, Moss-Morris R, Buchwald D, Crawley E, Hautvast J, et al. Long COVID and Post-Infective Fatigue Syndrome: A Review. Open Forum Infect Dis. 2021;8(10):ofab440. doi: 10.1093/ofid/ofab440.</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arena</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Faghy</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Cardiopulmonary Exercise Testing as a Vital Sign in Patients Recovering from COVID-19</article-title>
          <source>Expert Rev Cardiovasc Ther</source>
          <year>2021</year>
          <volume>19</volume>
          <issue>10</issue>
          <fpage>877</fpage>
          <lpage>880</lpage>
          <pub-id pub-id-type="doi">10.1080/14779072.2021.1985466</pub-id>
        </element-citation>
        <mixed-citation>5 Arena R, Faghy MA. Cardiopulmonary Exercise Testing as a Vital Sign in Patients Recovering from COVID-19. Expert Rev Cardiovasc Ther. 2021;19(10):877-80. doi: 10.1080/14779072.2021.1985466.</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holdsworth</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Barker-Davies</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Chamley</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>O&#8217;Sullivan</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ladlow</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>May</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cardiopulmonary Exercise Testing Excludes Significant Disease in Patients Recovering from COVID-19</article-title>
          <source>BMJ Mil Health</source>
          <year>2024</year>
          <volume>170</volume>
          <issue>4</issue>
          <fpage>308</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="doi">10.1136/military-2022-002193</pub-id>
        </element-citation>
        <mixed-citation>6 Holdsworth DA, Barker-Davies RM, Chamley RR, O&#8217;Sullivan O, Ladlow P, May S, et al. Cardiopulmonary Exercise Testing Excludes Significant Disease in Patients Recovering from COVID-19. BMJ Mil Health. 2024;170(4):308-14. doi: 10.1136/military-2022-002193.</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Joseph</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Heerdt</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Cullinan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lutchmansingh</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Gulati</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Persistent Exertional Intolerance after COVID-19: Insights from Invasive Cardiopulmonary Exercise Testing</article-title>
          <source>Chest</source>
          <year>2022</year>
          <volume>161</volume>
          <issue>1</issue>
          <fpage>54</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chest.2021.08.010</pub-id>
        </element-citation>
        <mixed-citation>7 Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, et al. Persistent Exertional Intolerance after COVID-19: Insights from Invasive Cardiopulmonary Exercise Testing. Chest. 2022;161(1):54-63. doi: 10.1016/j.chest.2021.08.010.</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stavrou</surname>
              <given-names>VT</given-names>
            </name>
            <name>
              <surname>Kyriaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vavougios</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Fatouros</surname>
              <given-names>IG</given-names>
            </name>
            <name>
              <surname>Metsios</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Kalabakas</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Athletes with Mild Post-COVID-19 Symptoms Experience Increased Respiratory and Metabolic Demands: A Cross-Sectional Study</article-title>
          <source>Sports Med Health Sci</source>
          <year>2023</year>
          <volume>5</volume>
          <issue>2</issue>
          <fpage>106</fpage>
          <lpage>111</lpage>
          <pub-id pub-id-type="doi">10.1016/j.smhs.2022.10.004</pub-id>
        </element-citation>
        <mixed-citation>8 Stavrou VT, Kyriaki A, Vavougios GD, Fatouros IG, Metsios GS, Kalabakas K, et al. Athletes with Mild Post-COVID-19 Symptoms Experience Increased Respiratory and Metabolic Demands: A Cross-Sectional Study. Sports Med Health Sci. 2023;5(2):106-11. doi: 10.1016/j.smhs.2022.10.004.</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baggish</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Battle</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Beckerman</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Bove</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Lampert</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>BD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sports Cardiology: Core Curriculum for Providing Cardiovascular Care to Competitive Athletes and Highly Active People</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2017</year>
          <volume>70</volume>
          <issue>15</issue>
          <fpage>1902</fpage>
          <lpage>1918</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2017.08.055</pub-id>
        </element-citation>
        <mixed-citation>9 Baggish AL, Battle RW, Beckerman JG, Bove AA, Lampert RJ, Levine BD, et al. Sports Cardiology: Core Curriculum for Providing Cardiovascular Care to Competitive Athletes and Highly Active People. J Am Coll Cardiol. 2017;70(15):1902-18. doi: 10.1016/j.jacc.2017.08.055.</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grimby</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>B&#246;rjesson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jonsdottir</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Schnohr</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Thelle</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Saltin</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The "Saltin-Grimby Physical Activity Level Scale" and its Application to Health Research</article-title>
          <source>Scand J Med Sci Sports</source>
          <year>2015</year>
          <volume>25</volume>
          <supplement>Suppl 4</supplement>
          <fpage>119</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="doi">10.1111/sms.12611</pub-id>
        </element-citation>
        <mixed-citation>10 Grimby G, B&#246;rjesson M, Jonsdottir IH, Schnohr P, Thelle DS, Saltin B. The "Saltin-Grimby Physical Activity Level Scale" and its Application to Health Research. Scand J Med Sci Sports. 2015;25(Suppl 4):119-25. doi: 10.1111/sms.12611.</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grossman</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Sellera</surname>
              <given-names>CAC</given-names>
            </name>
            <name>
              <surname>Hossri</surname>
              <given-names>CAC</given-names>
            </name>
            <name>
              <surname>Carreira</surname>
              <given-names>LTF</given-names>
            </name>
            <name>
              <surname>Avanza</surname>
              <given-names>AC</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Albuquerque</surname>
              <given-names>PF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Position Statement of the Brazilian Society of Cardiology Department of Exercise Testing, Sports Exercise, Nuclear Cardiology, and Cardiovascular Rehabilitation (DERC/SBC) on Activities Within its Scope of Practice During the COVID-19 Pandemic</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2020</year>
          <volume>115</volume>
          <issue>2</issue>
          <fpage>284</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="doi">10.36660/abc.20200797</pub-id>
        </element-citation>
        <mixed-citation>11 Grossman GB, Sellera CAC, Hossri CAC, Carreira LTF, Avanza AC Jr, Albuquerque PF, et al. Position Statement of the Brazilian Society of Cardiology Department of Exercise Testing, Sports Exercise, Nuclear Cardiology, and Cardiovascular Rehabilitation (DERC/SBC) on Activities Within its Scope of Practice During the COVID-19 Pandemic. Arq Bras Cardiol. 2020;115(2):284-91. doi: 10.36660/abc.20200797.</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braga</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Domecg</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kalichsztein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nobre</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kezen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Espinosa</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Abnormal Exercise Adaptation after Varying Severities of COVID-19: A Controlled Cross-Sectional Analysis of 392 Survivors</article-title>
          <source>Eur J Sport Sci</source>
          <year>2023</year>
          <volume>23</volume>
          <issue>5</issue>
          <fpage>829</fpage>
          <lpage>839</lpage>
          <pub-id pub-id-type="doi">10.1080/17461391.2022.2054363</pub-id>
        </element-citation>
        <mixed-citation>12 Braga F, Domecg F, Kalichsztein M, Nobre G, Kezen J, Espinosa G, et al. Abnormal Exercise Adaptation after Varying Severities of COVID-19: A Controlled Cross-Sectional Analysis of 392 Survivors. Eur J Sport Sci. 2023;23(5):829-39. doi: 10.1080/17461391.2022.2054363.</mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Milani</surname>
              <given-names>JGPO</given-names>
            </name>
            <name>
              <surname>Cipriano</surname>
              <given-names>GFB</given-names>
            </name>
            <name>
              <surname>Cahalin</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cipriano</surname>
              <given-names>G</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Cardiopulmonary Exercise Testing in Post-COVID-19 Patients: Where does Exercise Intolerance Come from?</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2023</year>
          <volume>120</volume>
          <issue>2</issue>
          <elocation-id>e20220150</elocation-id>
          <pub-id pub-id-type="doi">10.36660/abc.20220150</pub-id>
        </element-citation>
        <mixed-citation>13 Milani M, Milani JGPO, Cipriano GFB, Cahalin LP, Stein R, Cipriano G Jr. Cardiopulmonary Exercise Testing in Post-COVID-19 Patients: Where does Exercise Intolerance Come from? Arq Bras Cardiol. 2023;120(2):e20220150. doi: 10.36660/abc.20220150.</mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Milani</surname>
              <given-names>JGPO</given-names>
            </name>
            <name>
              <surname>Cipriano</surname>
              <given-names>GFB</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cipriano</surname>
              <given-names>G</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Reference Standards for Cardiorespiratory Fitness in Brazil: A Pooled Analysis and Overview of Heterogeneity in National and International Studies</article-title>
          <source>J Cardiopulm Rehabil Prev</source>
          <year>2022</year>
          <volume>42</volume>
          <issue>5</issue>
          <fpage>366</fpage>
          <lpage>372</lpage>
          <pub-id pub-id-type="doi">10.1097/HCR.0000000000000690</pub-id>
        </element-citation>
        <mixed-citation>14 Milani M, Milani JGPO, Cipriano GFB, Castro I, Cipriano G Jr. Reference Standards for Cardiorespiratory Fitness in Brazil: A Pooled Analysis and Overview of Heterogeneity in National and International Studies. J Cardiopulm Rehabil Prev. 2022;42(5):366-72. doi: 10.1097/HCR.0000000000000690.</mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rose</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Davison</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>MH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Cardiopulmonary Exercise Test Grey Zone; Optimising Fitness Stratification by Application of Critical Difference</article-title>
          <source>Br J Anaesth</source>
          <year>2018</year>
          <volume>120</volume>
          <issue>6</issue>
          <fpage>1187</fpage>
          <lpage>1194</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bja.2018.02.062</pub-id>
        </element-citation>
        <mixed-citation>15 Rose GA, Davies RG, Davison GW, Adams RA, Williams IM, Lewis MH, et al. The Cardiopulmonary Exercise Test Grey Zone; Optimising Fitness Stratification by Application of Critical Difference. Br J Anaesth. 2018;120(6):1187-94. doi: 10.1016/j.bja.2018.02.062.</mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>&#346;li&#380;</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wiecha</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ulaszewska</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>G&#261;sior</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Lewandowski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kasiak</surname>
              <given-names>PS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>COVID-19 and Athletes: Endurance Sport and Activity Resilience Study-CAESAR Study</article-title>
          <source>Front Physiol</source>
          <year>2022</year>
          <volume>13</volume>
          <fpage>1078763</fpage>
          <lpage>1078763</lpage>
          <pub-id pub-id-type="doi">10.3389/fphys.2022.1078763</pub-id>
        </element-citation>
        <mixed-citation>16 &#346;li&#380; D, Wiecha S, Ulaszewska K, G&#261;sior JS, Lewandowski M, Kasiak PS, et al. COVID-19 and Athletes: Endurance Sport and Activity Resilience Study-CAESAR Study. Front Physiol. 2022;13:1078763. doi: 10.3389/fphys.2022.1078763.</mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parpa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Michaelides</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Aerobic Capacity of Professional Soccer Players Before and after COVID-19 Infection</article-title>
          <source>Sci Rep</source>
          <year>2022</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>11850</fpage>
          <lpage>11850</lpage>
          <pub-id pub-id-type="doi">10.1038/s41598-022-16031-7</pub-id>
        </element-citation>
        <mixed-citation>17 Parpa K, Michaelides M. Aerobic Capacity of Professional Soccer Players Before and after COVID-19 Infection. Sci Rep. 2022;12(1):11850. doi: 10.1038/s41598-022-16031-7.</mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D&#8217;Isabel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Berny</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Frost</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thongphok</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jack</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chaudhry</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Effect of Mild to Moderate COVID-19 Infection on the Cardiorespiratory Fitness of Firefighters</article-title>
          <source>Front Public Health</source>
          <year>2023</year>
          <volume>11</volume>
          <fpage>1308605</fpage>
          <lpage>1308605</lpage>
          <pub-id pub-id-type="doi">10.3389/fpubh.2023.1308605</pub-id>
        </element-citation>
        <mixed-citation>18 D&#8217;Isabel S, Berny LM, Frost A, Thongphok C, Jack K, Chaudhry S, et al. The Effect of Mild to Moderate COVID-19 Infection on the Cardiorespiratory Fitness of Firefighters. Front Public Health. 2023;11:1308605. doi: 10.3389/fpubh.2023.1308605.</mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cho</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessing Stress and Anxiety in Firefighters During the Coronavirus Disease-2019 Pandemic: A Comparative Adaptation of the Stress and Anxiety in the Viral Epidemic-9 Items and Stress and Anxiety in the Viral Epidemics-6 Items Scales</article-title>
          <source>Psychiatry Investig</source>
          <year>2023</year>
          <volume>20</volume>
          <issue>11</issue>
          <fpage>1095</fpage>
          <lpage>1102</lpage>
          <pub-id pub-id-type="doi">10.30773/pi.2023.0260</pub-id>
        </element-citation>
        <mixed-citation>19 Cho IK, Lee HS, Song K, Ahmed O, Lee D, Kim J, et al. Assessing Stress and Anxiety in Firefighters During the Coronavirus Disease-2019 Pandemic: A Comparative Adaptation of the Stress and Anxiety in the Viral Epidemic-9 Items and Stress and Anxiety in the Viral Epidemics-6 Items Scales. Psychiatry Investig. 2023;20(11):1095-102. doi: 10.30773/pi.2023.0260.</mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Csulak</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Petrov</surname>
              <given-names>&#193;</given-names>
            </name>
            <name>
              <surname>Kov&#225;ts</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tokodi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lakatos</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kov&#225;cs</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Impact of COVID-19 on the Preparation for the Tokyo Olympics: A Comprehensive Performance Assessment of Top Swimmers</article-title>
          <source>Int J Environ Res Public Health</source>
          <year>2021</year>
          <volume>18</volume>
          <issue>18</issue>
          <fpage>9770</fpage>
          <lpage>9770</lpage>
          <pub-id pub-id-type="doi">10.3390/ijerph18189770</pub-id>
        </element-citation>
        <mixed-citation>20 Csulak E, Petrov &#193;, Kov&#225;ts T, Tokodi M, Lakatos B, Kov&#225;cs A, et al. The Impact of COVID-19 on the Preparation for the Tokyo Olympics: A Comprehensive Performance Assessment of Top Swimmers. Int J Environ Res Public Health. 2021;18(18):9770. doi: 10.3390/ijerph18189770.</mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Hsieh</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Two Weeks of Detraining Reduces Cardiopulmonary Function and Muscular Fitness in Endurance Athletes</article-title>
          <source>Eur J Sport Sci</source>
          <year>2022</year>
          <volume>22</volume>
          <issue>3</issue>
          <fpage>399</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1080/17461391.2021.1880647</pub-id>
        </element-citation>
        <mixed-citation>21 Chen YT, Hsieh YY, Ho JY, Lin TY, Lin JC. Two Weeks of Detraining Reduces Cardiopulmonary Function and Muscular Fitness in Endurance Athletes. Eur J Sport Sci. 2022;22(3):399-406. doi: 10.1080/17461391.2021.1880647.</mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pitanga</surname>
              <given-names>FJG</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>MDC</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Mill</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Giatti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Molina</surname>
              <given-names>MDCB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Leisure Time Physical Activity and SARS-CoV-2 Infection among ELSA-Brasil Participants</article-title>
          <source>Int J Environ Res Public Health</source>
          <year>2022</year>
          <volume>19</volume>
          <issue>21</issue>
          <fpage>14155</fpage>
          <lpage>14155</lpage>
          <pub-id pub-id-type="doi">10.3390/ijerph192114155</pub-id>
        </element-citation>
        <mixed-citation>22 Pitanga FJG, Almeida MDC, Duncan BB, Mill JG, Giatti L, Molina MDCB, et al. Leisure Time Physical Activity and SARS-CoV-2 Infection among ELSA-Brasil Participants. Int J Environ Res Public Health. 2022;19(21):14155. doi: 10.3390/ijerph192114155.</mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahmati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shamsi</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Khoramipour</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Malakoutinia</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Woo</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Baseline Physical Activity is Associated with Reduced Mortality and Disease Outcomes in COVID-19: A Systematic Review and Meta-Analysis</article-title>
          <source>Rev Med Virol</source>
          <year>2022</year>
          <volume>32</volume>
          <issue>5</issue>
          <elocation-id>e2349</elocation-id>
          <pub-id pub-id-type="doi">10.1002/rmv.2349</pub-id>
        </element-citation>
        <mixed-citation>23 Rahmati M, Shamsi MM, Khoramipour K, Malakoutinia F, Woo W, Park S, et al. Baseline Physical Activity is Associated with Reduced Mortality and Disease Outcomes in COVID-19: A Systematic Review and Meta-Analysis. Rev Med Virol. 2022;32(5):e2349. doi: 10.1002/rmv.2349.</mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwendinger</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Knaier</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Radtke</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schmidt-Trucks&#228;ss</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Low Cardiorespiratory Fitness Post-COVID-19: A Narrative Review</article-title>
          <source>Sports Med</source>
          <year>2023</year>
          <volume>53</volume>
          <issue>1</issue>
          <fpage>51</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1007/s40279-022-01751-7</pub-id>
        </element-citation>
        <mixed-citation>24 Schwendinger F, Knaier R, Radtke T, Schmidt-Trucks&#228;ss A. Low Cardiorespiratory Fitness Post-COVID-19: A Narrative Review. Sports Med. 2023;53(1):51-74. doi: 10.1007/s40279-022-01751-7.</mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herbec</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kale</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Shahab</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lally</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Correlates of and Changes in Aerobic Physical Activity and Strength Training Before and after the Onset of COVID-19 Pandemic in the UK: Findings from the HEBECO Study</article-title>
          <source>BMJ Open</source>
          <year>2022</year>
          <volume>12</volume>
          <issue>6</issue>
          <elocation-id>e054029</elocation-id>
          <pub-id pub-id-type="doi">10.1136/bmjopen-2021-054029</pub-id>
        </element-citation>
        <mixed-citation>25 Herbec A, Schneider V, Fisher A, Kale D, Shahab L, Lally P. Correlates of and Changes in Aerobic Physical Activity and Strength Training Before and after the Onset of COVID-19 Pandemic in the UK: Findings from the HEBECO Study. BMJ Open. 2022;12(6):e054029. doi: 10.1136/bmjopen-2021-054029.</mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McIlroy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Passfield</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Holmberg</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Sperlich</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Virtual Training of Endurance Cycling - A Summary of Strengths, Weaknesses, Opportunities and Threats</article-title>
          <source>Front Sports Act Living</source>
          <year>2021</year>
          <volume>3</volume>
          <fpage>631101</fpage>
          <lpage>631101</lpage>
          <pub-id pub-id-type="doi">10.3389/fspor.2021.631101</pub-id>
        </element-citation>
        <mixed-citation>26 McIlroy B, Passfield L, Holmberg HC, Sperlich B. Virtual Training of Endurance Cycling - A Summary of Strengths, Weaknesses, Opportunities and Threats. Front Sports Act Living. 2021;3:631101. doi: 10.3389/fspor.2021.631101.</mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meier</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>N&#228;gler</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wald</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Purchasing Behavior and Use of Digital Sports Offers by CrossFit&#174; and Weightlifting Athletes during the First SARS-CoV-2 Lockdown in Germany</article-title>
          <source>BMC Sports Sci Med Rehabil</source>
          <year>2022</year>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>44</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.1186/s13102-022-00436-y</pub-id>
        </element-citation>
        <mixed-citation>27 Meier N, N&#228;gler T, Wald R, Schmidt A. Purchasing Behavior and Use of Digital Sports Offers by CrossFit&#174; and Weightlifting Athletes during the First SARS-CoV-2 Lockdown in Germany. BMC Sports Sci Med Rehabil. 2022;14(1):44. doi: 10.1186/s13102-022-00436-y.</mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Shaban</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <source>Home-Fitness Gear Surges During Pandemic [Internet]</source>
          <publisher-loc>Washington</publisher-loc>
          <publisher-name>Washington Post</publisher-name>
          <year>2022</year>
          <date-in-citation content-type="access-date">[cited 2025 Jul 21]</date-in-citation>
          <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.washingtonpost.com/road-to-recovery/2021/01/07/home-fitness-boom/">https://www.washingtonpost.com/road-to-recovery/2021/01/07/home-fitness-boom/</ext-link> </comment>
        </element-citation>
        <mixed-citation>28 Shaban H. Home-Fitness Gear Surges During Pandemic [Internet]. Washington: Washington Post; 2022 [cited 2025 Jul 21]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.washingtonpost.com/road-to-recovery/2021/01/07/home-fitness-boom/">https://www.washingtonpost.com/road-to-recovery/2021/01/07/home-fitness-boom/</ext-link>.</mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Bertrand</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Deprez</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ko</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zello</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Chilibeck</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
          <article-title>The Impact of the COVID-19 Pandemic on the Diet, Training Habits and Fitness of Masters Cyclists</article-title>
          <source>Nutr Health</source>
          <year>2022</year>
          <volume>28</volume>
          <issue>4</issue>
          <fpage>669</fpage>
          <lpage>675</lpage>
          <pub-id pub-id-type="doi">10.1177/02601060211002350</pub-id>
        </element-citation>
        <mixed-citation>29 Shaw KA, Bertrand L, Deprez D, Ko J, Zello GA, Chilibeck PD. The Impact of the COVID-19 Pandemic on the Diet, Training Habits and Fitness of Masters Cyclists. Nutr Health. 2022;28(4):669-75. doi: 10.1177/02601060211002350.</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="S1" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20250094i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cardiopulmonary Resilience in Highly Active Individuals: Pre&#8211;Post COVID-19 Cardiopulmonary Exercise Testing Analysis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Braga</surname>
            <given-names>Fabr&#237;cio</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Writing of the manuscript</role>
          <role>Acquisition of data</role>
          <xref ref-type="aff" rid="aff11">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff12">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Espinosa</surname>
            <given-names>Gabriel</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff11">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Monteiro</surname>
            <given-names>Amanda</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff11">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3688-2108</contrib-id>
          <name>
            <surname>Milani</surname>
            <given-names>Mauricio</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff13">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff14">
            <sup>4</sup>
          </xref>
          <xref ref-type="aff" rid="aff15">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paiva</surname>
            <given-names>Juliana</given-names>
          </name>
          <role>Analysis and interpretation of the data</role>
          <xref ref-type="aff" rid="aff11">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff16">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Milani</surname>
            <given-names>Juliana Goulart Prata Oliveira</given-names>
          </name>
          <role>Analysis and interpretation of the data</role>
          <xref ref-type="aff" rid="aff13">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff14">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-6327-1428</contrib-id>
          <name>
            <surname>Franzoni</surname>
            <given-names>Leandro</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff18">
            <sup>8</sup>
          </xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stein</surname>
            <given-names>Ricardo</given-names>
          </name>
          <role>Obtaining financing</role>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff18">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-6323-7003</contrib-id>
          <name>
            <surname>Cipriano</surname>
            <given-names>Gerson</given-names>
            <suffix>Jr.</suffix>
          </name>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <xref ref-type="aff" rid="aff17">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gurgel</surname>
            <given-names>Jonas L&#237;rio</given-names>
          </name>
          <role>Analysis and interpretation of the data</role>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff11">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff19">
            <sup>9</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-2501-302X</contrib-id>
          <name>
            <surname>Mourilhe-Rocha</surname>
            <given-names>Ricardo</given-names>
          </name>
          <role>Critical revision of the manuscript for content</role>
          <xref ref-type="aff" rid="aff12">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff20">
            <sup>10</sup>
          </xref>
        </contrib>
        <aff id="aff11">
          <label>1</label>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Laborat&#243;rio de Performance Humana, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff12">
          <label>2</label>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff13">
          <label>3</label>
          <addr-line>
            <named-content content-type="city">Bras&#237;lia</named-content>
            <named-content content-type="state">DF</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Programa de P&#243;s-Gradua&#231;&#227;o em Ci&#234;ncias e Tecnologias da Sa&#250;de, Universidade de Bras&#237;lia (UnB), Bras&#237;lia, DF &#8211; Brasil</institution>
        </aff>
        <aff id="aff14">
          <label>4</label>
          <addr-line>
            <named-content content-type="city">Hasselt</named-content>
          </addr-line>
          <country country="BR">B&#233;lgica</country>
          <institution content-type="original">Hasselt University, REVAL/BIOMED, Hasselt &#8211; B&#233;lgica</institution>
        </aff>
        <aff id="aff15">
          <label>5</label>
          <addr-line>
            <named-content content-type="city">Hasselt</named-content>
          </addr-line>
          <country country="BR">B&#233;lgica</country>
          <institution content-type="original">Heart Centre Hasselt, Jessa Hospital, Hasselt &#8211; B&#233;lgica</institution>
        </aff>
        <aff id="aff16">
          <label>6</label>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff17">
          <label>7</label>
          <addr-line>
            <named-content content-type="city">Bras&#237;lia</named-content>
            <named-content content-type="state">DF</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade de Bras&#237;lia, Bras&#237;lia, DF &#8211; Brasil</institution>
        </aff>
        <aff id="aff18">
          <label>8</label>
          <addr-line>
            <named-content content-type="city">Porto Alegre</named-content>
            <named-content content-type="state">RS</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal do Rio Grande do Sul, Porto Alegre, RS &#8211; Brasil</institution>
        </aff>
        <aff id="aff19">
          <label>9</label>
          <addr-line>
            <named-content content-type="city">Niter&#243;i</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal Fluminense, Niter&#243;i, RJ &#8211; Brasil</institution>
        </aff>
        <aff id="aff20">
          <label>10</label>
          <addr-line>
            <named-content content-type="city">Rio de Janeiro</named-content>
            <named-content content-type="state">RJ</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Complexo Hospitalar Am&#233;ricas- Vit&#243;ria e Samaritano Barra, Rio de Janeiro, RJ &#8211; Brasil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2"><label>Mailing Address:</label><bold>Leandro Franzoni</bold> &#8226; Universidade Federal do Rio Grande do Sul (UFRGS) &#8211; Rua Itabora&#237;, 683. Postal Code <postal-code>90040-060</postal-code>, Porto Alegre, RS &#8211; Brazil E-mail: <email>franzoni.esef@gmail.com</email> </corresp>
        <fn fn-type="conflict">
          <label>Potential conflict of interest</label>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
        <fn fn-type="edited-by">
          <label>Editor responsible for the review:</label>
          <p>Gl&#225;ucia Maria Moraes de Oliveira</p>
        </fn>
      </author-notes>
      <abstract>
        <title>Abstract</title>
        <sec>
          <title>Background:</title>
          <p>The COVID-19 pandemic has affected millions globally, with persistent impacts extending beyond the acute phase. One such effect is post-COVID (long COVID), characterized by symptoms such as fatigue and exercise intolerance lasting more than 60 days. Although regular exercise is associated with reduced risk of severe outcomes, reports of decreased athletic performance after COVID-19 &#8212; even among highly active individuals (HAIs) &#8212; have raised concerns regarding the long-term effects on physical health. Cardiopulmonary exercise testing (CPET) is a valuable tool to assess exercise intolerance and to investigate the metabolic and ventilatory consequences of COVID-19.</p>
        </sec>
        <sec>
          <title>Objectives:</title>
          <p>To evaluate the impact of COVID-19 on cardiopulmonary function in HAIs by analyzing metabolic and ventilatory responses using CPET before and after infection.</p>
        </sec>
        <sec>
          <title>Methods:</title>
          <p>CPET data were retrospectively analyzed from HAIs of both sexes. Primary outcomes included changes in peak oxygen uptake (<inline-formula id="in65"><mml:math display="inline" id="inm65"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak) and ventilatory efficiency (<inline-formula id="in66"><mml:math display="inline" id="inm66"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in67"><mml:math display="inline" id="inm67"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> slope). Statistical significance was set at 5% (p &lt; 0.05).</p>
        </sec>
        <sec>
          <title>Results:</title>
          <p>A total of 43 HAIs (72.1% male; 44 &#177; 10 years) were included. The median interval between CPETs was 479 days, with testing performed a mean of 44 &#177; 27 days after COVID-19. <inline-formula id="in68"><mml:math display="inline" id="inm68"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak decreased by a mean of 1.5 mL/kg/min (p = 0.017), representing a 3.84% reduction in predicted <inline-formula id="in69"><mml:math display="inline" id="inm69"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak values (p = 0.045). <inline-formula id="in70"><mml:math display="inline" id="inm70"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in71"><mml:math display="inline" id="inm71"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> slope increased by 1.2 (p = 0.017).</p>
        </sec>
        <sec>
          <title>Conclusion:</title>
          <p>Although HAIs are not immune to the effects of COVID-19, their high baseline physical activity levels appear to confer substantial cardiopulmonary resilience. Only minimal post-infection alterations were observed, which suggests that maintaining fitness may provide protective benefits against long-term sequelae of COVID-19.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords:</title>
        <kwd>Cardiorespiratory Fitness</kwd>
        <kwd>Exercise</kwd>
        <kwd>Exercise Test</kwd>
        <kwd>Athletic Performance</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico</funding-source>
          <award-id>444823/2023-9</award-id>
        </award-group>
        <funding-statement>This study was partially funded by Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior &#8211; Brasil (CAPES) (ROR identifier: 00x0ma614) e Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico (CNPq) (n&#186;444823/2023-9).</funding-statement>
      </funding-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introduction</title>
        <p>The COVID-19 pandemic, which began in December 2019 in Wuhan, China, has affected more than 600 million people and resulted in over 6 million deaths worldwide across five waves of infection over the past 3 years.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> COVID-19 symptoms are known to persist beyond the acute phase, resulting in post-acute sequelae referred to as long COVID syndrome, which is characterized by symptoms that last for more than 60 days.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup> Although the underlying mechanisms are not fully understood, fatigue and exercise intolerance are among the most frequently reported symptoms.<sup><xref ref-type="bibr" rid="B4">4</xref></sup></p>
        <p>Cardiopulmonary exercise testing (CPET) is the gold standard for evaluating exercise intolerance and is recommended for assessing individuals with long COVID.<sup><xref ref-type="bibr" rid="B5">5</xref>&#8211;<xref ref-type="bibr" rid="B7">7</xref></sup> Despite the well-established protective effects of regular physical activity and high cardiorespiratory fitness (CRF) against severe disease and its sequelae, even athletes have reported diminished physical performance following COVID-19 infection.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> CPET-based studies have described several abnormalities in this population, including reduced CRF, early onset of anaerobic metabolism, and altered ventilatory patterns. However, few studies have compared pre- and post-infection CPET data in physically active individuals.</p>
        <p>Therefore, the aim of this study was to compare metabolic and ventilatory responses using CPET performed before and after COVID-19 in highly active individuals (HAIs).<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
        <fig id="f4">
          <graphic xlink:href="1678-4170-abc-122-09-e20250094-50094-gf01-en.tif"/></fig>
      </sec>
      <sec sec-type="methods">
        <title>Methods</title>
        <p>This cross-sectional study involved an ex post facto analysis of CPET data collected between May 2020 and September 2022 at two sports cardiology centers. Individuals were eligible for inclusion if they met all of the following criteria: (1) age &#8805; 18 years; (2) level 4 on the Saltin-Grimby Physical Activity Level Scale (SGPALS), indicating intense regular training for competitive sports;<sup><xref ref-type="bibr" rid="B10">10</xref></sup> (3) CPET performed as part of a post&#8211;COVID-19 assessment prior to resuming high-volume or high-intensity competitive training; and (4) availability of a pre&#8211;COVID-19 CPET performed on the same ergometer.</p>
        <p>The study was approved by the ethics committees of both participating institutions (CAAE 33729120.5.0000.5253 and 35706720.4.0000.8093). All procedures were conducted in accordance with the 2013 World Medical Association Declaration of Helsinki.</p>
        <p>The CPET was performed using either a treadmill (Centurium 200) or an electromagnetically braked cycle ergometer (Schoberer Rad Me&#223;technik [SRM], Germany) with breath-by-breath gas analysis (Metalyzer 3B, Cortex). For cycle ergometer tests, bike geometry was adjusted based on individual preferences, and participants were advised to wear appropriate cycling attire. The protocol began with 2 minutes of rest followed by a 5-minute warm-up at a constant workload (100 W for men, 50 W for women). This was followed by a ramp protocol with workload increments of 25 W/min for men and 15 W/min for women, continuing until volitional exhaustion. Participants were instructed to maintain a cadence consistent with their usual training, with the test terminating when cadence dropped below 70 rpm despite verbal encouragement. For treadmill tests, an individualized ramp protocol was used, with the initial speed set between 4 and 6 km/h and increased linearly based on the participant's age and reported athletic performance. A slight incline increase (0.5% every 2 minutes) was incorporated to ensure progressive loading throughout the test. All procedures adhered to national recommendations for viral transmission mitigation.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
        <p>The protocol and methodology for ventilatory gas analysis, as previously described,<sup><xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref></sup> included pre-exercise spirometry to assess forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV<sup><xref ref-type="bibr" rid="B1">1</xref></sup>). CPET variables analyzed included oxygen consumption (<inline-formula id="in72"><mml:math display="inline" id="inm72"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>), heart rate (HR), breathing frequency (BF), tidal volume (TV), and ventilation (<inline-formula id="in73"><mml:math display="inline" id="inm73"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E) at the first (VT<sup><xref ref-type="bibr" rid="B1">1</xref></sup>) and second (VT<sup><xref ref-type="bibr" rid="B2">2</xref></sup>) ventilatory thresholds, as well as at peak exercise. Ventilatory efficiency was assessed using the ventilatory equivalent for carbon dioxide (<inline-formula id="in74"><mml:math display="inline" id="inm74"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in75"><mml:math display="inline" id="inm75"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>) at VT<sup><xref ref-type="bibr" rid="B1">1</xref></sup>, VT<sup><xref ref-type="bibr" rid="B2">2</xref></sup>, peak, and as the <inline-formula id="in76"><mml:math display="inline" id="inm76"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in77"><mml:math display="inline" id="inm77"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> slope.</p>
        <p>An experienced physician determined ventilatory thresholds and peak values. The <inline-formula id="in78"><mml:math display="inline" id="inm78"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in79"><mml:math display="inline" id="inm79"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> slope was calculated up to VT<sup><xref ref-type="bibr" rid="B2">2</xref></sup>. <inline-formula id="in80"><mml:math display="inline" id="inm80"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak and <inline-formula id="in81"><mml:math display="inline" id="inm81"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E were defined as the highest 30-second moving average recorded during the final minute of exertion. Predicted <inline-formula id="in82"><mml:math display="inline" id="inm82"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak values were based on nationally established reference standards and were used to classify CRF.<sup><xref ref-type="bibr" rid="B14">14</xref></sup></p>
        <p>The percentage change (&#916;%) in <inline-formula id="in83"><mml:math display="inline" id="inm83"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak and <inline-formula id="in84"><mml:math display="inline" id="inm84"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in85"><mml:math display="inline" id="inm85"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> was calculated as the difference between post&#8211;COVID-19 and pre&#8211;COVID-19 values, divided by the pre&#8211;COVID-19 value. These changes were compared with the critical differences (CD) proposed by Rose et al. (2018) &#8212; 13% for <inline-formula id="in86"><mml:math display="inline" id="inm86"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak and 10% for <inline-formula id="in87"><mml:math display="inline" id="inm87"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in88"><mml:math display="inline" id="inm88"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>.<sup><xref ref-type="bibr" rid="B15">15</xref></sup> This threshold was used to determine whether the observed changes were potentially clinically and biologically relevant.</p>
        <sec>
          <title>Statistical analysis</title>
          <p>Since the exploratory nature of this study, a priori sample size calculation was not performed. Instead, a comprehensive design was employed, including all individuals who met the eligibility criteria. Continuous variables were reported as mean &#177; standard deviation (SD) for normally distributed data or as median with interquartile range (25th percentile; 75th percentile) for non-normally distributed data, as determined by the Shapiro-Wilk test. Paired <italic>t</italic> tests were used to compare parametric data, while the Wilcoxon signed rank test was used for nonparametric data. Median differences for nonparametric variables were estimated using the Hodges-Lehmann method.</p>
          <p>Statistical significance was set at p &lt; 0.05 for all analyses. All statistical procedures were performed using IBM SPSS Statistics for Windows, version 29.0 (IBM Corp., Armonk, N.Y., USA).</p>
        </sec>
      </sec>
      <sec sec-type="results">
        <title>Results</title>
        <p><xref ref-type="fig" rid="f3">Figure 1</xref> presents the patient inclusion flowchart. A total of 43 HAIs met the inclusion criteria and were included in the analysis (72.1% male; 42 &#177; 10 years). The mean time from COVID-19 diagnosis to post-infection CPET was 44 &#177; 27 days. The median interval between pre- and post-infection CPET was 479 days (IQR, 546 days). CPET was performed using a cycle ergometer in 55.8% of cases. Nearly all participants experienced mild acute illness, and none required hospitalization.</p>
        <fig id="f3">
          <label>Figure 2</label>
          <caption>
            <title>Patient inclusion flowchart based on the inclusion criteria. CPET: cardiopulmonary exercise testing; HAI: highly active individual.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-122-09-e20250094-50094-gf02-en.tif"/></fig>
        <p><xref ref-type="table" rid="t2">Table 1</xref> summarizes CPET variables before and after COVID-19. No significant changes were observed in spirometry parameters (FVC and FEV<sup><xref ref-type="bibr" rid="B1">1</xref></sup>). However, minor yet statistically significant changes were noted in selected CPET variables. Both <inline-formula id="in89"><mml:math display="inline" id="inm89"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> at VT<sup><xref ref-type="bibr" rid="B2">2</xref></sup> and <inline-formula id="in90"><mml:math display="inline" id="inm90"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak showed slight decreases. The median percentage change in <inline-formula id="in91"><mml:math display="inline" id="inm91"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak was below the &#8722;13% threshold for clinical significance (p &#8804; 0.001). Only six participants (14%) exhibited a decrease in <inline-formula id="in92"><mml:math display="inline" id="inm92"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak exceeding this threshold after COVID-19.</p>
        <table-wrap id="t2">
          <label>Table 1</label>
          <caption>
            <title>Cardiopulmonary exercise test variables before and after COVID-19 infection in highly active individuals</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="20%">
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
              <tr style="background-color:#76B4CF;">
                <th align="left" valign="middle">Variable</th>
                <th align="center" valign="middle">Before COVID-19</th>
                <th align="center" valign="middle">After COVID-19</th>
                <th align="center" valign="middle">Paired difference (95%CI)</th>
                <th align="center" valign="middle">p-value</th>
              </tr>
            </thead>
            <tbody style="border-bottom: thin solid; border-color: #000000">
              <tr style="background-color:#76B4CF;">
                <td align="left" colspan="5" valign="middle">
                  <bold>Spirometry</bold>
                  <xref ref-type="table-fn" rid="TFN8">b</xref>
                </td>
              </tr>
              <tr>
                <td align="left" valign="middle">FVC, L<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">4.75 &#177; 1.00</td>
                <td align="center" valign="middle">4.78 &#177; 1.03</td>
                <td align="center" valign="middle">&#8722;0.07 (&#8722;0.26 a &#8722;0.12)</td>
                <td align="center" valign="middle">0.455</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">FEV<sub>1</sub>, L<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">3.79 &#177; 0.74</td>
                <td align="center" valign="middle">3.86 &#177; 0.84</td>
                <td align="center" valign="middle">0.003 (&#8722;0.10 a 0.10)</td>
                <td align="center" valign="middle">0.956</td>
              </tr>
              <tr style="background-color:#76B4CF;">
                <td align="left" colspan="5" style="border-top: thin solid; border-color: #000000" valign="middle">
                  <bold>CPET</bold>
                </td>
              </tr>
              <tr>
                <td align="left" valign="middle">VO<sub>2</sub>peak, l/min<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">3.52 &#177; 0.74</td>
                <td align="center" valign="middle">3.42 &#177; 0.71</td>
                <td align="center" valign="middle">&#8722;0.10 (&#8722;0.20 a 0.002)</td>
                <td align="center" valign="middle">0.055</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">VO<sub>2</sub>peak, ml/kg/min<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">47.3 &#177; 7.1</td>
                <td align="center" valign="middle">45.8 &#177; 7.3</td>
                <td align="center" valign="middle">&#8722;1.5 (&#8722;2.79 a &#8722;0.29)</td>
                <td align="center" valign="middle">0.017</td>
              </tr>
              <tr>
                <td align="left" valign="middle">VO<sub>2</sub>peak, % do predicted<xref ref-type="table-fn" rid="TFN10">d</xref> </td>
                <td align="center" valign="middle">123.0 (111.3&#8211;141.2)</td>
                <td align="center" valign="middle">118.4 (109.6&#8211;137.0)</td>
                <td align="center" valign="middle">&#8722;3.84 (&#8722;7.9 a &#8722;0.08)</td>
                <td align="center" valign="middle">0.045</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">Peak HR, bpm<xref ref-type="table-fn" rid="TFN10">d</xref> </td>
                <td align="center" valign="middle">174 (165&#8211;181)</td>
                <td align="center" valign="middle">173 (163&#8211;182)</td>
                <td align="center" valign="middle">&#8722;0.5 (&#8722;2.5 a 1.5)</td>
                <td align="center" valign="middle">0.647</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Peak <inline-formula id="in93"><mml:math display="inline" id="inm93"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E, l/min<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">138.4 &#177; 32.6</td>
                <td align="center" valign="middle">134.4 &#177; 29.8</td>
                <td align="center" valign="middle">&#8722;4.0 (&#8722;9.5 a 1.6)</td>
                <td align="center" valign="middle">0.159</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">Peak TV, l<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">2.66 &#177; 0.59</td>
                <td align="center" valign="middle">2.67 &#177; 0.62</td>
                <td align="center" valign="middle">0.01 (&#8722;0.07 a 0.08)</td>
                <td align="center" valign="middle">0.792</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Peak BF, breaths/min<xref ref-type="table-fn" rid="TFN10">d</xref> </td>
                <td align="center" valign="middle">54.0 (46.5&#8211;58.0)</td>
                <td align="center" valign="middle">49.7 (45.0&#8211;57.0)</td>
                <td align="center" valign="middle">&#8722;1.5 (&#8722;3.5 a 0.35)</td>
                <td align="center" valign="middle">0.079</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">Peak <inline-formula id="in94"><mml:math display="inline" id="inm94"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in95"><mml:math display="inline" id="inm95"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub><xref ref-type="table-fn" rid="TFN10">d</xref> </td>
                <td align="center" valign="middle">32.6 (31.3&#8211;34.7)</td>
                <td align="center" valign="middle">34.2 (32.0&#8211;36.6)</td>
                <td align="center" valign="middle">1.2 (0.25 a 2.20)</td>
                <td align="center" valign="middle">0.017</td>
              </tr>
              <tr>
                <td align="left" valign="middle">I<inline-formula id="in96"><mml:math display="inline" id="inm96"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in97"><mml:math display="inline" id="inm97"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>slope<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">30.7 &#177; 4.0</td>
                <td align="center" valign="middle">31.3 &#177; 4.0</td>
                <td align="center" valign="middle">0.63 (&#8722;0.30 a 1.56)</td>
                <td align="center" valign="middle">0.176</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">OUES<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">3727 &#177; 868</td>
                <td align="center" valign="middle">3474 &#177; 1025</td>
                <td align="center" valign="middle">&#8722;253 (&#8722;508 a 1)</td>
                <td align="center" valign="middle">0.051</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Peak RER<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">1.16 &#177; 0.07</td>
                <td align="center" valign="middle">1.15 &#177; 0.07</td>
                <td align="center" valign="middle">&#8722;0.01 (&#8722;0.03 a 0.01)</td>
                <td align="center" valign="middle">0.453</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">VO<sub>2</sub> at VT<sub>1</sub>, l/min<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">2.26 &#177; 0.54</td>
                <td align="center" valign="middle">2.21 &#177; 0.49</td>
                <td align="center" valign="middle">&#8722;0.06 (&#8722;0.19 a 0.07)</td>
                <td align="center" valign="middle">0.366</td>
              </tr>
              <tr>
                <td align="left" valign="middle">VO<sub>2</sub> at VT<sub>1</sub>, ml/kg/min<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">30.6 &#177; 6.2</td>
                <td align="center" valign="middle">29.3 &#177; 7.5</td>
                <td align="center" valign="middle">&#8722;1.34 (&#8722;3.54 a 0.86)</td>
                <td align="center" valign="middle">0.226</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">FC at VT<sub>1</sub>, bpm<xref ref-type="table-fn" rid="TFN10">d</xref> </td>
                <td align="center" valign="middle">133 (119&#8211;144)</td>
                <td align="center" valign="middle">133 (119&#8211;144)</td>
                <td align="center" valign="middle">0.00 (&#8722;4.0 a 4.5)</td>
                <td align="center" valign="middle">0.913</td>
              </tr>
              <tr>
                <td align="left" valign="middle"><inline-formula id="in98"><mml:math display="inline" id="inm98"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>C at VT1, l/min<xref ref-type="table-fn" rid="TFN10">d</xref></td>
                <td align="center" valign="middle">58.8 (46.3&#8211;71.1)</td>
                <td align="center" valign="middle">61.2 (49.5&#8211;69.3)</td>
                <td align="center" valign="middle">0.7 (&#8722;4.3 a 5.8)</td>
                <td align="center" valign="middle">0.213</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">FR at VT1, breaths/min<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">28.8 &#177; 6.9</td>
                <td align="center" valign="middle">28.1 &#177; 7.0</td>
                <td align="center" valign="middle">&#8722;0.7 (&#8722;2.0 a 0.7)</td>
                <td align="center" valign="middle">0.330</td>
              </tr>
              <tr>
                <td align="left" valign="middle">VC at VT1, l<xref ref-type="table-fn" rid="TFN10">d</xref> </td>
                <td align="center" valign="middle">1.96 (1.70&#8211;2.55)</td>
                <td align="center" valign="middle">2.20 (1.70&#8211;2.63)</td>
                <td align="center" valign="middle">0.07 (&#8722;0.06 a 0.21)</td>
                <td align="center" valign="middle">0.817</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle"><inline-formula id="in99"><mml:math display="inline" id="inm99"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in100"><mml:math display="inline" id="inm100"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> at VT1<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">29.3 &#177; 4.0</td>
                <td align="center" valign="middle">29.3 &#177; 3.4</td>
                <td align="center" valign="middle">0.01 (&#8722;0.94 a 0.96)</td>
                <td align="center" valign="middle">0.980</td>
              </tr>
              <tr>
                <td align="left" valign="middle">VO<sub>2</sub> at VT<sub>2</sub>, l/min<xref ref-type="table-fn" rid="TFN10">d</xref> </td>
                <td align="center" valign="middle">3.36 (2.76&#8211;3.59)</td>
                <td align="center" valign="middle">2.96 (2.67&#8211;3.50)</td>
                <td align="center" valign="middle">&#8722;0.11 (&#8722;0.25 a 0.02)</td>
                <td align="center" valign="middle">0.085</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">VO<sub>2</sub> at VT<sub>2</sub>, ml/kg/min<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">42.4 &#177; 6.0</td>
                <td align="center" valign="middle">40.6 &#177; 6.5</td>
                <td align="center" valign="middle">&#8722;1.71 (&#8722;3.32 a &#8722;0.10)</td>
                <td align="center" valign="middle">0.038</td>
              </tr>
              <tr>
                <td align="left" valign="middle">FC at VT<sub>2</sub>, bpm<xref ref-type="table-fn" rid="TFN10">d</xref> </td>
                <td align="center" valign="middle">163 (155&#8211;173)</td>
                <td align="center" valign="middle">161 (150&#8211;169)</td>
                <td align="center" valign="middle">&#8722;0.5 (&#8722;3.5 a 2.5)</td>
                <td align="center" valign="middle">0.507</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle"><inline-formula id="in101"><mml:math display="inline" id="inm101"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E at VT<sub>2</sub>, l/min<xref ref-type="table-fn" rid="TFN10">d</xref></td>
                <td align="center" valign="middle">107.8 (82.8&#8211;119.4)</td>
                <td align="center" valign="middle">93.2 (83.8&#8211;113.3)</td>
                <td align="center" valign="middle">&#8722;3.7 (&#8722;8.5 a 1.43)</td>
                <td align="center" valign="middle">0.158</td>
              </tr>
              <tr>
                <td align="left" valign="middle">FR at VT<sub>2</sub>, breaths/min<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">39.4 &#177; 8.1</td>
                <td align="center" valign="middle">37.6 &#177; 8.0</td>
                <td align="center" valign="middle">&#8722;1.8 (&#8722;3.50 a &#8722;0.06)</td>
                <td align="center" valign="middle">0.043</td>
              </tr>
              <tr style="background-color:#C7DFEC;">
                <td align="left" valign="middle">VC at VT<sub>2</sub>, l<xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">2.61 &#177; 0.60</td>
                <td align="center" valign="middle">2.62 &#177; 0.59</td>
                <td align="center" valign="middle">0.01 (&#8722;0.08 a 0.10)</td>
                <td align="center" valign="middle">0.833</td>
              </tr>
              <tr>
                <td align="left" valign="middle"><inline-formula id="in102"><mml:math display="inline" id="inm102"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in103"><mml:math display="inline" id="inm103"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> at VT<sub>2</sub><xref ref-type="table-fn" rid="TFN9">c</xref> </td>
                <td align="center" valign="middle">30.3 &#177; 3.1</td>
                <td align="center" valign="middle">30.6 &#177; 3.2</td>
                <td align="center" valign="middle">0.31 (&#8722;0.42 a 1.04)</td>
                <td align="center" valign="middle">0.398</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN6">
              <p>Data are presented as mean &#177; SD or median (IQR), as appropriate.</p>
            </fn>
            <fn id="TFN7">
              <label>a</label>
              <p>Paired difference = post&#8211;COVID-19 minus pre&#8211;COVID-19 value; 95%CI provided.</p>
            </fn>
            <fn id="TFN8">
              <label>b</label>
              <p>Spirometry data available for 30 individuals.</p>
            </fn>
            <fn id="TFN9">
              <label>c</label>
              <p>Paired t test used.</p>
            </fn>
            <fn id="TFN10">
              <label>d</label>
              <p>Wilcoxon signed rank test used; Hodges-Lehmann method applied for median differences. BF: breathing frequency; CPET: cardiopulmonary exercise testing; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; HR: heart rate; OUES: oxygen uptake efficiency slope; RER: respiratory exchange ratio; <inline-formula id="in104"><mml:math display="inline" id="inm104"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E: ventilation; <inline-formula id="in105"><mml:math display="inline" id="inm105"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in106"><mml:math display="inline" id="inm106"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO2: ventilatory equivalent for carbon dioxide; VO<sub>2</sub>: oxygen uptake; VT: ventilatory threshold; TV: tidal volume.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>The peak <inline-formula id="in107"><mml:math display="inline" id="inm107"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in108"><mml:math display="inline" id="inm108"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> ratio increased significantly following COVID-19. However, no other ventilatory efficiency parameters demonstrated significant changes. The median percentage change in peak <inline-formula id="in109"><mml:math display="inline" id="inm109"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in110"><mml:math display="inline" id="inm110"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> was below the 10% CD threshold (p &lt; 0.001). Only two participants (4.7%) exhibited an increase exceeding the CD.</p>
        <p>BF at VT<sup><xref ref-type="bibr" rid="B2">2</xref></sup> showed a slight post&#8211;COVID-19 reduction. Although statistically significant, these changes were not clinically or biologically meaningful and cannot be definitively attributed to post&#8211;COVID-19 effects or to reduced training volume during recovery.</p>
      </sec>
      <sec sec-type="discussion">
        <title>Discussion</title>
        <p>This study evaluated the impact of COVID-19 infection on HAIs and identified minor reductions in oxygen consumption at both peak exercise and the VT<sup><xref ref-type="bibr" rid="B2">2</xref></sup>, along with a slight increase in the peak <inline-formula id="in111"><mml:math display="inline" id="inm111"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in112"><mml:math display="inline" id="inm112"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> ratio. Although statistically significant, these changes did not indicate major cardiopulmonary impairment. Moreover, all observed variations remained below established CD thresholds, which suggests they are unlikely to reflect clinically meaningful effects of COVID-19 on cardiopulmonary function. Central Illustration summarizes the main findings of the study.</p>
        <p>Few studies have assessed CPET results in HAIs before and after COVID-19 infection. &#346;li&#380; et al.<sup><xref ref-type="bibr" rid="B16">16</xref></sup> reported a significant reduction in <inline-formula id="in113"><mml:math display="inline" id="inm113"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak as well as <inline-formula id="in114"><mml:math display="inline" id="inm114"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> at VT<sup><xref ref-type="bibr" rid="B1">1</xref></sup> and VT<sup><xref ref-type="bibr" rid="B2">2</xref></sup> among endurance athletes. Similar to our findings, their study documented a 5.9% decrease in <inline-formula id="in115"><mml:math display="inline" id="inm115"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak &#8212; a change not conclusively attributable to COVID-19. Our study contributes further insight, with a higher proportion of female participants (27.9% vs 12.2%) and a shorter interval between COVID-19 infection and post-infection CPET (44 vs 155 days), thereby enhancing the current understanding of the potential impact of COVID-19 on cardiopulmonary function in HAIs.</p>
        <p>Parpa &amp; Michaelides<sup><xref ref-type="bibr" rid="B17">17</xref></sup> evaluated CRF in professional soccer players before and after COVID-19 and reported significantly lower <inline-formula id="in116"><mml:math display="inline" id="inm116"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>max values and treadmill running time post-infection, even after 60 days of recovery, which suggests a lasting impact on CRF. Together, these results highlight the potential long-term effects of COVID-19 on aerobic performance in athletes. Notably, neither the study by Parpa &amp; Michaelides<sup><xref ref-type="bibr" rid="B17">17</xref></sup> nor that by &#346;li&#380; et al.<sup><xref ref-type="bibr" rid="B16">16</xref></sup> included assessments of ventilatory efficiency.</p>
        <p>In the study by D&#8217;Isabel et al.<sup><xref ref-type="bibr" rid="B18">18</xref></sup> involving firefighters from Arizona, significant post&#8211;COVID-19 reductions were observed in both <inline-formula id="in117"><mml:math display="inline" id="inm117"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak and <inline-formula id="in118"><mml:math display="inline" id="inm118"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> at VT<sup><xref ref-type="bibr" rid="B1">1</xref></sup>. The mean decrease in <inline-formula id="in119"><mml:math display="inline" id="inm119"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak was 2.55 mL/kg/min, corresponding to a 7.3% reduction &#8212; the largest reported to date. <inline-formula id="in120"><mml:math display="inline" id="inm120"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> at VT<sup><xref ref-type="bibr" rid="B1">1</xref></sup> declined even more substantially, by 24.3%. Additionally, ventilatory efficiency worsened, as indicated by an increase in the <inline-formula id="in121"><mml:math display="inline" id="inm121"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in122"><mml:math display="inline" id="inm122"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub> slope from 24.7 pre-infection to 26.0 post-infection. Unlike competitive athletes, firefighters from Arizona have distinct physical training regimens and occupational demands, which may have influenced their recovery trajectories. Demographic factors and regional characteristics may also have contributed to the observed outcomes. The physically demanding nature of their work, combined with the added pressure of responding to emergency calls during the pandemic, likely introduced heightened stress, potentially impairing cardiopulmonary recovery and differentiating their experience from that of athletic populations.<sup><xref ref-type="bibr" rid="B19">19</xref></sup></p>
        <p>Conversely, Csulak et al.<sup><xref ref-type="bibr" rid="B20">20</xref></sup> conducted a study on elite swimmers, evaluating cardiopulmonary performance before and after COVID-19 infection. Their results showed no significant changes in key CPET parameters, including <inline-formula id="in123"><mml:math display="inline" id="inm123"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>max and <inline-formula id="in124"><mml:math display="inline" id="inm124"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>E/<inline-formula id="in125"><mml:math display="inline" id="inm125"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>CO<sub>2</sub>, which suggests that mild COVID-19 infection had minimal impact on the cardiopulmonary function of high-level athletes.</p>
        <p>The observed changes in aerobic capacity post-COVID-19 among HAIs may not solely be attributed to the virus. A study on endurance athletes indicated that just two weeks of detraining can significantly reduce cardiopulmonary function and muscular fitness. This suggests that the reduction in training during recovery from COVID-19 could contribute to the decreased aerobic performance observed in our study.<sup><xref ref-type="bibr" rid="B21">21</xref></sup> Therefore, it is crucial to consider the impact of reduced training activity when interpreting changes in cardiopulmonary function post-COVID-19.</p>
        <p>The minimal changes observed in maximal aerobic power (<inline-formula id="in126"><mml:math display="inline" id="inm126"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak) and the preservation of submaximal oxidative capacity (<inline-formula id="in127"><mml:math display="inline" id="inm127"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub> at VT<sup><xref ref-type="bibr" rid="B1">1</xref></sup>) in our cohort may be attributed to several factors. Prior research has demonstrated that physical activity can serve as a protective factor against severe illness, including COVID-19.<sup><xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref></sup> Reductions in CRF after COVID-19 have been associated with severe disease, older age, sedentary behavior, and comorbidities.<sup><xref ref-type="bibr" rid="B24">24</xref></sup> In contrast, the athletic lifestyle, absence of comorbidities, and relative youth of the individuals in our study likely contributed to the preservation of CRF. Furthermore, the COVID-19 pandemic affected exercise behavior in diverse ways. The increase in physical activity among individuals during this period is estimated to range from 9% to 33%.<sup><xref ref-type="bibr" rid="B25">25</xref></sup> For example, virtual cycling training saw marked growth, fueled by lockdown measures, technological advancements, and the endorsement of major events such as the Tour de France,<sup><xref ref-type="bibr" rid="B26">26</xref></sup> accompanied by a 170% increase in indoor training equipment sales.<sup><xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref></sup> Shaw et al.<sup><xref ref-type="bibr" rid="B29">29</xref></sup> also reported no change in training volume among master cyclists during confinement. These findings suggest that some individuals may have reached a peak in aerobic conditioning before infection, and the post&#8211;COVID-19 values observed in our study could represent a return to baseline rather than a true decline in cardiopulmonary function.</p>
        <p>This study has several important limitations. First, the equivalence of pre&#8211;COVID-19 physiological parameters with true baseline values is uncertain. Second, post&#8211;COVID-19 training behaviors and illness severity were self-reported, which introduces potential recall bias. Third, the inclusion of only mild COVID-19 cases limits the generalizability of findings to individuals who experienced moderate or severe illness. Fourth, the lack of a less active control group restricts the ability to make comparative inferences. Fifth, data collection occurred during the early stages of the COVID-19 pandemic, prior to vaccine availability and the emergence of later viral variants. While this limits applicability to other phases of the pandemic, it also provides a unique snapshot of the initial impact of COVID-19 on HAIs. Sixth, the study population &#8212; characterized by a mean age of 42 years and a <inline-formula id="in128"><mml:math display="inline" id="inm128"><mml:mrow><mml:mover><mml:mtext>V</mml:mtext><mml:mo>&#8901;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>O<sub>2</sub>peak of 47 mL/kg/min &#8212; reflects a group that is highly active but not at an elite athletic level. Therefore, the findings may not be generalizable to either elite athletes or less active individuals. Seventh, the use of different ergometers (cycle vs treadmill) and the absence of sex-specific analyses may have introduced additional variability in physiological measurements. Finally, the lack of a true control group limits the ability to distinguish post&#8211;COVID-19 changes from normal physiological fluctuations related to training interruptions or unrelated factors. Future studies incorporating control groups and a broader range of fitness levels will be essential to provide more comprehensive, generalizable insights.</p>
      </sec>
      <sec sec-type="conclusions">
        <title>Conclusion</title>
        <p>This comprehensive analysis of HAIs compared CPET results before and after the onset of the COVID-19 pandemic. The results demonstrated the body's remarkable cardiopulmonary resilience in the context of high physical fitness. Although minor changes in cardiopulmonary function were observed, these remained below CD thresholds, which suggests a preserved capacity to withstand and recover from the physiological impacts of COVID-19. These findings support the potential protective role of an active lifestyle against the adverse effects of emerging infectious diseases.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="financial-disclosure" id="fn1">
          <label>Sources of funding</label>
          <p>This study was partially funded by Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior &#8211; Brasil (CAPES) (ROR identifier: 00x0ma614) e Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico (CNPq) (n&#176;444823/2023-9).</p>
        </fn>
        <fn fn-type="other" id="fn2">
          <label>Study association</label>
          <p>This study is not associated with any thesis or dissertation work.</p>
        </fn>
        <fn fn-type="other" id="fn3">
          <label>Ethics approval and consent to participate</label>
          <p>This study was approved by the Ethics Committee of the Laborat&#243;rio de Performance Humana and the Universidade de Bras&#237;lia, respectively under the protocol number 33729120.5.0000.5253 e 35706720.4.0000.8093. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p>
        </fn>
        <fn fn-type="other" id="fn4">
          <label>Use of Artificial Intelligence</label>
          <p>The authors did not use any artificial intelligence tools in the development of this work.</p>
        </fn>
      </fn-group>
      <sec sec-type="data-availability" specific-use="data-available">
        <label>Data Availability</label>
        <p>The underlying content of the research text is contained within the manuscript.</p>
      </sec>
    </back>
  </sub-article>
</article>
